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Abstract 
 
Cytosine methylation (5mC) is essential for transcriptional control and genomic 
stability and is often used as a prognostic marker in cancer. Although 5mC has long been 
considered a relatively stable epigenetic mark, recent studies have demonstrated that it can 
be reversed enzymatically by TET proteins which oxidize 5mC into 5-
hydroxymethylcytosine (5-hmC), and then to 5-formylcytosine (5-fC) and 5-carboxylcytosine 
(5caC). This mechanism is known as active DNA demethylation and the base excision repair 
enzyme Thymine DNA Glycosylase (TDG) plays an essential role in this process by removing 
5-fC and 5-caC which are subsequently replaced by the unmethylated cytosine. Importantly, 
homozygous loss of TDG in mice causes embryonic lethality and the observed defects are 
consistent with a central role for TDG in active demethylation and protein scaffolding events. 
I hypothesize that the dual catalytic and protein scaffolding activities of TDG are essential 
for gene transcription and that TDG functions as a tumor suppressor in vivo by maintaining 
epigenetic stability in cells.  
In this study, I investigated the regulation of Hypermethylated in Cancer 1 (Hic1) 
tumor suppressor to demonstrate that the dual catalytic and scaffolding activities of TDG 
are essential for gene transcription of HIC1. In addition, I developed a conditional TDG 
knockout mouse model to determine the role of TDG in development. Hic1 transcription 
involves a transient accumulation of 5fC/5caC metabolites and the recruitment of an 
RAR/RXR complex, both of which were found to be TDG dependent. Tdg deletion in vivo 
causes Hic1 silencing via promoter DNA hypermethylation. In addition, a loss of TDG in 
adult mice predisposes them to a high prevalence of hepatocellular carcinoma (HCC), 
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independent of cirrhosis or fibrosis. Surprisingly, HCC occurred predominantly in male 
mice, which also showed increased obesity compared to age matched controls.  RNAseq 
analysis of livers from TDG deleted mice showed downregulation of several metabolism 
relevant genes. These findings are consistent with an onset of HCC via the non-alcoholic fatty 
liver pathway.  Collectively, this study shows that the dual catalytic and scaffolding activities 
of TDG are required in gene transcription events, and provides the first evidence of TDG as 
a tumor suppressor of liver cancers.  
 
Key Words: Hepatocellular carcinoma, non-cirrhotic/fibrotic pathway, NAFLD, active DNA 
demethylation, TDG, TETs, HIC1, retinoic acid signaling 
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Chapter 1: Introduction 
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1.1  Epigenetic control of gene expression 
The term “epigenetics” was first coined in 1942 to describe changes in an organisms 
phenotype that occur independent of alterations in the DNA sequence (Waddington, 1942a, 
1942b). The field of epigenetics gained prominence with the discovery of the histone code, which 
along with DNA methylation, assists in gene expression by modulating the structure of chromatin 
(Waddington, 1942a). Chromatin consists of condensed units of DNA, protein and RNA, and its 
function is to package the genetic material into a more compact structure, prevent DNA damage 
and control gene expression and replication (Barrero et al., 2010). Histones are the primary protein 
components of chromatin, which facilitate DNA compaction through polar-polar interactions 
between their positively charged tails and the negatively charged DNA backbone.  DNA 
methylation is a chemical modification of the cytosine nucleotides, and its major function has been 
classically to repress gene transcription.  Numerous studies have now shown that epigenetic 
mechanisms, in addition to the DNA sequence, work to modulate specific gene expression patterns 
that dictate a multitude of cellular processes, such as signaling cascades in response to stimuli, and 
cellular reprogramming (Barrero et al., 2010; Métivier et al., 2008). The technological advances 
in next generation sequencing and biochemical techniques, such as chromatin 
immunoprecipitation and bisulfite sequencing, have enabled the analysis of the epigenome at or 
near base-pair resolution and allowed epigenetic profiling in both normal and abnormal cells or 
tissues. Most of these studies have demonstrated that epigenetic modifications of the chromatin 
are dynamic and have defined critical DNA control elements, such as promoters and enhancers 
(Chen et al., 2003b; Hassan et al., 2017; Iurlaro et al., 2016; Kolovos et al., 2012; Song et al., 
2013).  
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The concept of nucleosome organization of chromatin was first proposed in 1974 as a 
“chromatin subunit model” (Kornberg, 1974). In this model, it was proposed that chromatin is 
composed of an array of nucleosome core particles. Each nucleosome consists of a stretch of DNA 
(147 base pairs) wound around a histone octamer, which contains two copies of H2A, H2B, H3, 
and H4. The individual nucleosome particles are separated by approximately 50 base pairs of linker 
DNA and the linker histone H1. Furthermore, each histone possesses a positively charged N-
terminal tail that protrudes outwards and can be covalently modified. The compaction of chromatin 
into higher-order structures is mediated primarily by the N-terminal tails of histones H3 and H4, 
which bind to the DNA and interact with acidic regions of histones within the neighboring 
nucleosomes. Histone H1 binds the nucleosome at entry and exit sites of DNA, thus stabilizing the 
formation of higher order chromatin structures. Posttranslational modifications (PTMs) of the 
positively charged histone tails (e.g. acetylation, phosphorylation, and methylation) alters the 
structure of chromatin and either provides access to gene material or facilitates further DNA 
compaction. This remodeling of histone octamers, and thus the nucleosomes, leads to distinct 
states of the chromatin generally characterized as heterochromatin and euchromatin, that reflect 
different levels of gene activity (Allfrey et al., 1964; Allshire and Ekwall, 2015; Elgin and Reuter, 
2013; Kayne et al., 1988; Megee et al., 1990; Pikaard et al., 2014; Verdin and Ott, 2014). 
When stained with DAPI, heterochromatin appear as small, darkly staining, irregular 
particles scattered throughout the nucleus that consist of tightly packed nucleosomes. The 
heterochromatinization of DNA hinders gene transcription by masking binding sites for 
transcription factors, RNA polymerases and other proteins essential for gene expression. These 
heterochromatinized states are established by specific PTMs of the histone tails, such as 
trimethylation of H3K27 or di- and tri-methylation of H3K9. These marks are deposited by a 
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multitude of coregulator proteins such as SUV39H1 (Melcher et al., 2000), which are often found 
as part of larger protein complexes. For instance, the methylation of H3K9 (H3K9me3) by 
SUV39H1 provides a docking site for chromodomain-containing heterchromatin protein 1 (HP1), 
which then impairs nucleosome accessibility and induces gene repression (Bannister et al., 2001; 
Melcher et al., 2000; Stewart et al., 2005).  
In contrast, euchromatin consists of loosely packed chromatin and is enriched in genes 
which are either poised or undergoing active transcription. Approximately 90% of the genome is 
found in euchromatin. Many studies have now shown that acetylation of histone tails such as 
H3K14 acetylation (H3K14ac) by nuclear histone-acetyltransferases, such as CBP and p55, 
provide docking sites for bromodomain-containing proteins that further stimulate nucleosome 
accessibility and transcriptional activity (Allfrey et al., 1964; Verdin and Ott, 2014). Furthermore, 
covalent modifications affecting the histone tails can be reversed by histone deacetylases 
(HDACs), which remove acetylCoA and re-establish the repressed chromatin state (Nagy et al., 
1997; Verdin and Ott, 2014). The balance between euchromatin and heterochromatin formation of 
DNA, via the deposition and removal of specific histone marks, afford a powerful and highly 
conserved route to gene expression. Evidence for this is provided by the HP1-SUV39H1-H3K9 
histone methylation system for gene repression which is now known to be conserved across uni-
cellular organisms, plants, invertebrates and complex multicellular organisms (Allshire and 
Ekwall, 2015; Elgin and Reuter, 2013; Pikaard et al., 2014).  
 
1.2  DNA methylation 
    In addition to the covalent modification of histones, the methylation of cytosine at the 
5th carbon (5-mC) is the second major mechanism associated with epigenetic changes that has a 
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profound effect on gene expression. This modification occurs predominantly in the context of CpG 
dinucleotides (Wu and Zhang, 2014), which are palindromic sequences of cytosine followed by a 
guanine nucleotide. These dinucleotides are typically methylated in a symmetric fashion.  Regions 
with a high frequency of CpG sites (~ 60 % CpG composition) are referred to as CpG islands and 
occur at or near the promoters of mammalian genes, where they act to repress gene transcription 
when they are methylated. DNA methylation is also found within gene bodies of actively 
transcribed genes, regulatory elements such as enhancers, and non-CpG promoters depending on 
the cell type, although the role of CpG islands in these contexts remains unclear (Ito et al., 2011; 
Shen et al., 2014; Wu et al., 2014).  Roughly 60 – 80 % of CpG sites within the mammalian genome 
are methylated (Smith and Meissner, 2013).  Although the methylation of cytosine in non-CpG 
context is prevalent in plants (Wu and Zhang, 2014), the 5mC mark in mammalian cells is most 
commonly found in CpG sites.   
 The 5mC modification is important for a variety of biological processes including 
transcriptional regulation, genomic imprinting, X-chromosome inactivation and the suppression 
of mobile genetic elements (Wu and Zhang, 2014; Zhu, 2009). The deposition of the 5mC mark is 
known to affect the transcription of genes in two ways. First, in the context of promoter CpG 
islands, cytosine methylation contributes to transcriptional repression by affecting the affinity of 
transcription factors for their binding sites. For example, methylation of the E-box DNA element 
(CACGTG) prevents Myc from binding to the EGFR promoter in a cell-specific manner (Perini et 
al., 2005). Secondly, the 5mC mark can also provide docking sites for proteins containing the 
methyl binding domain (MBD). MBD proteins, such as MBD4 and MeCP2, are able to recruit 
additional effector proteins such as histone deacetylases and methyltransferases which can modify 
histones and increase chromatin compaction to further promote transcriptional repression (Fuks et 
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al., 2003).  Another example of crosstalk between DNA methylation and histone modifications is 
found in the repressive action of the G9A histone methyltransferase protein. G9A deposits 
repressive methylation marks on histones and physically recruits the DNA methyltransferase 
(DNMT) protein, which methylates DNA to suppress gene transcription  (Estève et al., 2006). 
DNA methylation in this example is not a cause, but a consequence of repression and serves to fix 
the repressed state of chromatin.  Evidence for the repressive role of 5mC is demonstrated by 
studies using epigenetic drugs such as 5-azacytidine, a chemical analogue of the nucleoside 
cytodine, that becomes incorporated into DNA and RNA and inhibits DNA methyltransferase 
causing hypomethylation of the DNA.  This results in transcriptional activation of genes silenced 
by promoter DNA hypermethylation (Britschgi et al., 2008; Kafri et al., 1992).   
 While it is clear that cytosine methylation is a crucial gene regulatory mechanism, several 
studies have challenged the notion that DNA methylation is always correlated with transcriptional 
repression. For example, the transcription of some genes has been found to be independent of 
methylation and in some cases, methylation is required for transcriptional activation and therefore, 
is positively correlated with gene expression (Bird, 1984).  Promoters with low CpG content are 
usually methylated, yet they still may be transcriptionally active (Weber et al., 2007) Intergenic 
and gene terminal CpG islands of some genes are frequently methylated, yet the genes they are 
associated with are transcriptionally active (Medvedeva et al., 2010). The dynamic nature of DNA 
methylation and proteins involved in this pathway will be the topic of discussion in the next 
section.  
1.3 DNA methylation is dynamic 
The 5mC mark is faithfully reproduced over successive replication cycles by the 
maintenance DNA methyltransferase 1 (DNMT1) protein, which catalyzes the transfer of a methyl 
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group from S-adenosylmethionine (SAM) to the C5 carbon of cytosine. In contrast, de novo 
DNMTs (DNMT2, DNMT3a and DNMT3b) can deposit novel methylation marks on DNA in a 
cell cycle independent manner. Despite cytosine methylation being primarily restricted to CpG 
sites in somatic cells, which are symmetrically methylated, non-CpG methylation is relatively 
abundant in oocytes, embryonic stem cells and mature neurons (Lister et al., 2009).  
Although 5mC has long been considered a relatively stable epigenetic mark, recent studies 
have demonstrated that DNA methylation, like histone modifications, is highly dynamic. There 
are multiple pathways that have been proposed to demethylate 5mC: active modification of 5mC 
followed by excision via TDG (active demethylation), passive dilution of 5mC and/or its oxidized 
metabolites (passive demethylation) and direct removal of the 5mC mark.  
The first evidence of active DNA demethylation was provided by studies showing that the 
interleukin 2 promoter undergoes rapid DNA demethylation following T lymphocyte activation, 
in a replication independent manner (Bruniquel and Schwartz, 2003). At that time, a unified 
mechanism responsible for active demethylation was not definitively established. One mechanism 
which has gained momentum involves base excision repair (BER) initiated by the DNA 
glycosylase, thymine DNA glycosylase (TDG). It was subsequently demonstrated that the 
promoters of several developmentally regulated genes underwent DNA hypermethylation upon 
deletion of TDG in mice (Cortazar et al., 2011; Cortellino et al., 2011). Further studies 
demonstrated that 5mC is not a direct substrate for TDG but is oxidized by Ten eleven translocase 
(TET) family of proteins to 5-hydroxymethylcytosine (5-hmC), and then to 5-formylcytosine (5-
fC) and 5-carboxylcytosine (5caC) (Ito et al., 2011) (Figure 1.1B). 5fC and 5caC are recognized 
and removed by TDG. This generates an abasic site which is then cleaved by AP endonuclease 
and the unmethylated cytosine is then incorporated by DNA polymerase.   
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The Ten eleven translocase (TET) proteins are iron (II)/ α-ketoglutarate (Fe(II)/α-KG)-
dependent dioxygenases that oxidize 5mC.  TET proteins contain a core double-stranded β-helix 
(DSBH) domain and a cysteine-rich (CXXC) domain. The DSBH domain of TETs brings the 
Fe(II), α-KG and 5mC together in a catalytic pocket to facilitate 5mC oxidation, whereas, the 
CXXC domain stabilizes the TET-DNA interaction. The full length TETs (TET1 and TET3) 
contain both the DSBH and CXXC domains, whereas, the truncated TET2 lacks CXXC domain 
(Wu and Zhang, 2017). Overall, these studies provide evidence of an active mechanism of DNA 
demethylation, where oxidation of the methyl group produces metabolites that can be processed 
by TDG and the BER pathway. 
In passive DNA demethylation, the 5mC mark is diluted over successive replication cycles by 
the deactivation or nuclear exclusion of maintenance DNMT1 or its associated co-factor, UHRF1 
(Kohli and Zhang, 2013) (Figure 1.1A). Evidence for passive demethylation can be found in 
studies on the role of demethylation metabolites in embryonic development.  Immunostaining of 
the early embryo has shown that loss of 5mC in the paternal genome is concomitant with 
generation of  5hmC metabolites, which is dependent on the expression of TET3 protein—the only 
highly expressed TET in the embryo (Gu et al., 2011; Guo et al., 2014; Tsukada et al., 2015). 
Knockdown or the targeted germline deletion of TET3 abolished the oxidation of 5mC in the 
paternal genome and led to reduced fertility and developmental failure in the offspring (Gu et al., 
2011; Guo et al., 2014). Despite finding that only the paternal DNA undergoes 5mC oxidation, 
both the maternal and paternal genomes are demethylated via passive dilution (Wu and Zhang, 
2014). The reason for selective oxidation of the paternal genome is currently unclear. On another 
note, although the passive demethylation pathway proceeds via dilution of the methylated DNA 
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strand to regenerate cytosine, the initial oxidation of 5mC is an active process. Hence, it is useful 
to consider this process as partially active rather than entirely passive.  
  In addition to passive dilution, the simplest route to regenerate unmethylated cytosine is a 
direct removal of the 5mC mark. This process poses a very large energy barrier due to the high 
stability of the covalent bond (carbon to carbon) linking the methyl group to C5 of cytosine. 
However, despite this energy barrier, plants utilize DEMETER/ROS1 class of proteins which 
directly remove 5mC without any oxidative modification of 5mC (Mok et al., 2010; Morales-Ruiz 
et al., 2006). In mammals, however, orthologues for DEMETER/ROS1 have not been identified 
so the most widely accepted mechanisms for restoring unmethylated cytosine involves two 
pathways: passive dilution and active DNA demethylation. Active demethylation involves 
oxidation of 5mC followed by replacement of oxidized substrates by TDG and members of the 
BER pathway.  
 
1.4 Role of TDG in active DNA demethylation 
 
Prior to the discovery of 5mC oxidation, initial studies on active demethylation supported a 
mechanism involving the deamination pathway (Nabel et al., 2012; Piccolo and Fisher, 2014; 
Thillainadesan et al., 2012; Zhu, 2009). It is well established that 5mC can be deaminated to 
thymine by the AID/APOBEC family of enzymes. This would generate a G-T mispair which is 
then excised by TDG. In addition, it was proposed that AID/APOBEC could deaminate 5hmC to 
5-hydroxymethyluracil (5hmU) which is then excised by TDG.  However, a study by Nabel et al. 
(2012) refuted this model since AID/APOBEC proteins were found to have little to no deamination 
activity on either 5mC or 5hmC in vitro (Nabel et al., 2012).  In contrast, AID/APOBEC displayed 
the highest preference towards the less bulky unmethylated cytosine nucleotide due to reduced 
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steric hindrance. These findings were further supported by the observation that there are no 
significant developmental defects associated with AID/APOBEC deficiency. Overall, these results 
suggest that deamination-coupled demethylation is unlikely to be involved in active 
demethylation, and that this process likely proceeds via a TET and TDG-dependant pathway. 
Unlike other proteins in its class, TDG is the only glycosylase essential for embryonic 
development (Cortázar et al., 2011; Cortellino et al., 2011). Homozygous loss of Tdg in the embryo 
correlated with decreased expression of developmental transcription factors with a marked 
increase in methylation at many regulatory sites.  This led both studies to conclude that TDG is 
required to maintain epigenetic stability in cells. Surprisingly it was demonstrated that 5mC or 
5hmC are not direct substrates for TDG. As stated above, 5mC and 5hmC could be metabolized 
further by TET proteins to 5fC and 5caC (Ito et al, 2011).  Importantly, biochemical studies 
demonstrated that TDG possesses robust activity against 5fC and 5caC when paired with G in vitro 
and in vivo (Shen et al., 2013; Maiti et al., 2011; He et al., 2010).  TDG was found to have a very 
high affinity for these metabolites and studies using mouse embryonic stem cells demonstrated 
that 5fC/5caC intermediates can be found at low levels throughout the genome and accumulate 
upon TDG deletion  (Hu et al., 2014; Shen et al., 2013, 2014; Spruijt et al., 2013; Wu et al., 2014). 
These findings demonstrate that TDG acts directly on TET oxidation products.   
In the TET/TDG model of active DNA demethylation, TDG catalyzes the excision of 5-fC and 
5-caC metabolites. This forms an apurinic (AP) site and the combined actions of APE1, DNA pol 
β and XRCC1- DNA ligase IIIα complex subsequently replace the AP site with an unmethylated 
cytosine (Figure 1.1B).  In this model, TDG functions as the focal point between TET mediated 
5mC oxidation and BER, which underscores its importance in maintenance of epigenetic stability  
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Figure 1. 1  The 5mC mark can be removed by both passive and active processes 
 
(A) Passive DNA demethylation is initiated by the silencing or nuclear exclusion of DNMT or its 
associated cofactor UHRF1. This pathway leads to loss of the maintenance methylation machinery 
and the methylated DNA strand is diluted over successive replication cycles. The methylated DNA 
strand is colored in blue. 
(B) TET- and TDG-mediated active DNA demethylation. DNMT’s deposit the methylation mark 
on cytosine (C) at the 5th carbon. Then, TET proteins successively oxidize the 5-methylcytosine 
(5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxycytosine 
(5caC). The 5fC and 5caC intermediates are excised by TDG leading to an apurinic (AP) site that 
is repaired by proteins from the base excision repair (BER) pathway: APE1, DNA pol β, and 
XRCC1-DNA ligase IIIα complex and unmethylated cytosine is restored.  The “R” group 
represents the deoxyribose sugar component of the nucleotide.   
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in cells. The mechanism of recognition and subsequent excision of 5fC/5caC by TDG is the topic 
of discussion in the next section. 
 
1.5 Structure of the TDG protein 
Thymine DNA glycosylase is a BER protein that belongs to the uracil DNA glycosylase 
(UDG) superfamily of enzymes that share a common α/β fold (Aravind and Koonin, 2000; Aravind 
et al., 2000; Cortázar et al., 2007; Mol et al., 1995; Neddermann and Jiricny, 1993; Pearl, 2000; 
Wiebauer and Jiricny, 1989). It was first purified from HeLa cell extracts and its initial biochemical 
properties were consistent with a central role in removing mutagenic 5-methylcytosine 
deamination products from DNA (Neddermann and Jiricny, 1993). TDG is capable of recognizing 
G:T and G:U mismatches in the DNA and restore the correct G:C base pairs through BER 
(Cortazar et al., 2007).  
The human TDG (410 amino acids) consists of a highly conserved catalytic core (121 – 300 
amino acids) that is flanked by variable amino and carboxyl terminal domains (Cortázar et al., 
2007) (Figure 2). The amino and carboxy termini of TDG contain sites for SUMO conjugation 
(K330 and E310), whereas, the carboxyl terminal domain enhances its affinity for DNA and 
contains the catalytic activity (Cortázar et al., 2007; McLaughlin et al., 2016). The terminal 
domains have also been shown to mediate diverse physical interactions with various nuclear 
receptors and other transcription factors and could potentially dictate targeting of TDG to specific 
DNA loci via accommodating specific interactions with its partners. TDG has also been shown to 
interact with numerous chromatin remodeling enzymes and DNMTs (Cortázar et al., 2007, 2011; 
Li et al., 2007), raising the possibility of a functional role of TDG in modulating gene transcription, 
either through its glycosylase activity or as a scaffold protein  and/or transcriptional coactivator.  
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1.6 Mechanism of action of TDG  
TDG has been the subject of compelling structural studies since the discovery of its unique 
role in recognition and excision of 5fC/5caC metabolites, as well as, T:G mispairs from DNA. The 
crystal structure of TDG catalytic domain bound to DNA revealed a 2:1 dimeric complex with the 
DNA, with one subunit being positioned at the abasic site forming the product complex, and the 
other at a non-specific site roughly 10 base pairs away (Maiti et al., 2008). The dimer was found 
to exist exclusively in the presence of DNA. Although the biological roles of dimer formation 
remain unclear, it could play an important role in transcriptional regulation through potential 
interactions with DNMT’s, chromatin remodeling proteins or co-activators such as CBP/ p300.  
 Upon binding to DNA, TDG causes the nucleotide to flip out of the double-helix and into the 
active site. The catalytic site of TDG forms various contacts with the abasic strand, involving 
phosphodiester groups flanking the abasic nucleotide, sugar and both guanines of the CpG site. 
The interactions with phosphates in the complementary strand is made by using side chains of 
K246 and K248, both of which are highly conserved in vertebrates. The phosphates belonging to 
the abasic nucleotide is displaced from the double helix and resides in the active-site pocket in a 
phenomenon called a “phosphate pinch” which facilitates nucleotide flipping. In the active site of 
TDG, residues 198- 200 cover the face of the flipped nucleotide, thereby preventing its re-insertion 
back into the double helix. Overall, the extensive interactions of TDG with the flipped nucleotide 
and backbone sugars of both DNA strands provides an explanation for the slow turnover of TDG 
bound DNA and its high affinity for the AP site (Baba et al., 2005; Cortázar et al., 2007; Maiti et 
al., 2008). 
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Figure 1. 2 Schematic representation of the TDG protein 
 
Schematic representation of wild type TDG and positions of the relevant amino acids and post-
translational modifications--Ac: acetylation site, DBD: DNA binding domain, NRs: nuclear 
receptors, SBD: SUMO binding domain, S: SUMOylation site 
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The crystal structure of TDG bound to 5caC-containing DNA confirmed a 2:1 binding, with 
the 5caC base being recognized by only one of the TDG molecules (Hashimoto et al., 2013; Zhang 
et al., 2012). TDG was found to bend the DNA backbone and flip 5caC out of the double helix, 
while R275 facilitates this process by wedging through the dsDNA minor groove and pushing 
5caC into the active site of TDG. The R275 amino acid enhances the nucleotide flipping 
mechanism, while simultaneously increasing DNA binding affinity of TDG. Overall, this 
remarkable “base-flipping” process involves rotation of the 5caC pyrimidine along the glycosylic 
bond, which causes the whole base to penetrate the active site pocket of TDG.  
Once inside the active site pocket of TDG, the 5caC base is locked via polar interactions from 
the surrounding amino acids: lle139, Ala140 and Asn191. In addition to these interactions, the 
carboxyl moiety of 5caC is specifically recognized in a small pocket formed via the side chains of 
several amino acids in the catalytic site. Particularly, the carboxyl group forms specific hydrogen 
bonding interactions with the backbone amide of Tyr152 and the side chain of Asn157, as well as, 
van der Waals contact with the side chain of Ala145. It is predicted that these polar interactions 
enhance the binding affinity of TDG for 5caC and 5fC metabolites over U and T.  
Kinetic studies on TDG demonstrate that it possesses little to no activity against 5mC, 5hmC 
or C paired with G in vitro (Waters and Swann, 1998). In contrast, TDG was shown to rapidly 
excise 5fC and 5caC from dsDNA with a Kmax of 2.64/min and 0.47/min, respectively (Waters and 
Swann, 1998). The preference for T:G mispairs fell between that of 5fC and 5caC, with a Kmax of 
1.83/min. These studies demonstrate that TDG can recognize 5fC and 5caC with high specificity, 
and through the base-flipping mechanism, facilitate the rapid excision of these metabolites from 
dsDNA. These unique characteristics position TDG as the only glycosylase capable of recognizing 
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and excising TET oxidation products from dsDNA and establishes its essential role in active DNA 
demethylation.  
 As discussed above, TDG has a very high affinity for the AP site, which makes the physical 
removal of TDG from DNA a rate limiting step in BER. Despite this potential roadblock for the 
repair pathway, the slow turnover of TDG is important since a naked AP site would predispose the 
DNA to single and double strand breaks. This could drastically increase the mutability and 
integrity of DNA over time.  
Many studies support the role of SUMOylation in facilitating TDG turnover from the AP site. 
Small Ubiquitin like Modifiers (SUMOs) are small peptides that interact with or are attached to 
other proteins (Jürgen Dohmen, 2004). Many of the SUMO target proteins participate in DNA 
replication or repair, which highlights its potential role in maintaining genome integrity and 
stability. SUMOylation induces a conformational change in the target proteins in a way that alters 
their protein:protein and/or protein: DNA interaction properties. In the case of TDG, SUMOylation 
at K330 causes protrusion of the C-terminal α helix and induces severe steric clash with the sugar-
phosphate backbone of the unpaired G (Baba et al., 2005). This in turn causes dissociation of 
SUMO-1-TDG from AP site.  Interestingly, the SUMOylation event doesn’t change the structure 
of SUMO-1, nor does it encounter steric interference from the DNA. 
Besides SUMOYlation of TDG, there are other proteins that affect its activity. Two of the most 
interesting proteins are GADD45 (growth arrest and DNA-damage-inducible protein 45) and NEIL 
(Nei endonuclease VIII-like family of DNA glycosylases). GADD45 is a multi-faceted nuclear 
protein which has been implicated in DNA demethylation, DNA repair and genomic stability. 
Overexpression of GADD45 leads to global DNA demethylation in the presence of TDG and TET 
proteins (Li et al., 2015). These studies propose that GADD45 enhances DNA demethylation by 
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TDG, although the mechanism remains unknown. NEILs, on the other hand, provide an alternative 
to SUMOYlation for facilitating TDG turnover by displacing TDG from the AP site and removing 
the baseless sugar. Interestingly, NEIL1 and 2 were also identified as 5fC binders and are 
implicated in excising these oxidized metabolites from genomic DNA, albeit at a much lower 
efficiency compared to TDG (Schomacher et al., 2016; Slyvka et al., 2017). Although the 
mechanism behind GADD45 and NEILs actions is unclear, the involvement of a wide multitude 
of proteins in TDG mediated active DNA demethylation highlights the complex nature of this 
process. 
 
1.7 Role of TDG in transcription regulation 
  TDG is the only glycosylase in mammals that is essential for embryonic development 
(Cortázar et al., 2011; Cortellino et al., 2011).  Tdg null embryos display a complex phenotype of 
liver and pericardial hemorrhages, hypoplastic branchial arteries, as well as delayed limb 
development. There were pronounced defects in the heart tissue, with prominent abnormalities in 
the outflow tract, vasculogenesis and angiogenesis. The consistency and sudden onset of lethality 
in Tdg null embryos was a very surprising observation, since a prominent role of TDG in base 
repair should have led to a more variable phenotype resulting from a wide spectrum of genetic 
mutations. However, mutations in the TDG KO mice were not identified and it became apparent 
from these studies that TDG plays a predominant role in transcriptional regulation in addition to 
BER.  
Tdg null embryos displayed 33% viability at E11.5 with complete reabsorption at E12.5, a 
time interval when the mouse genome undergoes epigenetic reprogramming and imprint erasure 
(Hackett et al., 2013). Loss of TDG at E11.5 caused gene expression defects of numerous 
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developmentally regulated genes most likely resulting from loss of recruitment of additional 
coregulators such as CBP/p300, as well DNA hypermethylation, the loss of active chromatin marks 
and the accumulation of repressive marks (Cortázar et al., 2011; Cortellino et al., 2011; Hajkova 
et al., 2010). These findings were consistent with a central role of TDG in transcription via gene-
specific DNA demethylation and establishment of histone marks during development. 
Interestingly, both knockout studies demonstrated that deletion of TDG in embryos severely 
impairs retinoid signaling pathways (Cortellino et al., 2011; Um et al., 1998). Furthermore, many 
of the phenotypical features observed in TDG null embryos were found to be common among 
RXR and RAR  null embryos (Cortellino et al., 2011).  TDG has also been shown to interact with 
RARα, RXRα and other nuclear receptors such as PPARα, ERα, TTF1, AR, TR, and GR (Chen 
et al., 2003a) 
In addition to interactions with nuclear receptors, TDG was found to associate with other 
transcription factors and coregulators such as TCF4, SRC1, SMADs, p/CIP, p53 and CBP/p300 
(Cortázar et al., 2007; Léger et al., 2014; Métivier et al., 2008; Thillainadesan et al., 2012; Tini et 
al., 2002). This comprehensive interaction network depicts TDG as a potential hub protein and an 
important player in protein complex stability at target genes.  Evidence for this was provided using 
chromatin immunoprecipitation studies showing that the recruitment of CBP, MLL1 and other 
proteins at target genes are lost upon TDG deletion (Cortellino et al., 2011).  This in turn affects 
gene expression due to the attenuated deposition of active histone marks, such as H3K4 tri-
methylation and H3K4 acetylation, which are more permissive for gene transcription.  
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1.8 Summary of objectives 
In lieu of the myriad of interactions of TDG with transcription factors, it became important 
to reconcile its glycosylase activity in gene transcription. The initial knockout papers demonstrated 
that a loss of TDG leads to gene specific hypermethylation, whereas, studies on mESC 
demonstrated a global accumulation of 5fC/5caC metabolites (Shen et al., 2013; Wu et al., 2014). 
Although these studies shed light on the relevance of TDG in active DNA demethylation, they 
show conflicting evidence and failed to provide a mechanism by which these metabolites are 
generated and excised by TDG. Furthermore, there is no study that reconciles the role of TDG 
dependent active DNA demethylation, involving the generation and excision of 5fC/5caC 
metabolites, and its scaffolding properties in gene regulation. First, to determine if the scaffolding 
and catalytic activities of TDG are important in gene regulation, I have examined its role in retinoid 
signaling events which was previously shown to be disrupted upon TDG deletion in embryos (Aim 
1).   Second, despite several studies implicating the importance of active DNA demethylation in 
embryonic development, little is known regarding the requirement for TDG in adult physiology. 
Hence, the second objective of my studies is to characterize the conditional deletion of TDG in 
adult mice and elucidate its role in post embryonic development (Aim 2). I hypothesize that active 
demethylation and the protein scaffolding activities of TDG are required for gene transcription and 
that TDG functions as a tumor suppressor in vivo that regulates gene expression by maintaining 
epigenetic stability in cells.  
 
Aim 1: Examine the role of TDG in retinoid signaling events (Chapter 2) 
In Chapter 2, I attempt to consolidate the dual catalytic and scaffolding activities of TDG 
in a single mechanistic model by focusing on its importance in retinoid signaling events.  Retinoic 
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acid (RA), the bioactive metabolite of vitamin A, plays a critical regulatory role during embryonic 
development, cellular homeostasis and differentiation of adult tissues by binding to heterodimers 
of retinoic acid receptor α (RARα) and retinoid X receptor α (RXRα) proteins (Tang and Gudas, 
2011). RA has also been characterized as a cell-cycle inhibitor by modulating the levels of p21CIP1 
and p27 KIP1 kinase inhibitors which arrest the cells in G0/G1 phase of mitosis (Li et al., 2004; Suzui 
et al., 2004).  The binding of RA to RARα induces a conformational change in the receptor that 
regulates the transcription of its target genes by recruiting coregulatory proteins (i.e. CBP/p300, 
SRC, TDG, p/CIP).  Interestingly, although RARs are rarely mutated in cancer, it has been reported 
that tumours lose sensitivity to RA often due to DNA hypermethylation of  retinoid regulated genes 
(Tang and Gudas, 2011).  
To examine the dual catalytic and scaffolding activities of TDG in RA signaling, we 
identified Hypermethylated in Cancer 1 gene (Hic1) as a novel RA inducible target and examined 
the mechanism of its regulation in mouse embryonic fibroblasts (MEFs). The Hic1 gene, located 
at genomic location 11p13.3, encodes a zinc-finger transcriptional repressor that belongs to the 
POZ family of proteins (Britschgi et al., 2008). HIC1 expression is often lost in solid human 
cancers and leukemia as a result of DNA hypermethylation of its promoter, which results in 
increased tumor cell proliferation, angiogenesis and metastasis (Aggerholm et al., 2006; Chen et 
al., 2003b; Cheng et al., 2014; Jenal et al., 2010).  Furthermore, studies have shown that HIC1 
expression in cancer can be restored via UV irradiation and 5-azacytidine (Britschgi et al., 2006), 
suggesting that mechanisms are in place for removing methylation. I show that treatment of MEFs 
with RA leads to a rapid recruitment of an RAR complex consisting of TDG, the lysine 
acetyltransferase CBP and TET1/2 to the Hic1 locus. The binding of this complex preceded loss 
of the 5mC mark, and the simultaneous accumulation of 5fC/5caC at the Hic1 promoter. Through 
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time-course methylase assisted bisulfite sequencing (MAB-seq), which allows the base resolution 
mapping of 5fC/5caC, I demonstrate that the subsequent excision of these metabolites occurs in a 
TDG dependent manner. In addition, I found that the recruitment of CBP and TET2 at Hic1 was 
TDG dependent, which is supported by a recent finding that TDG interacts with all three TET 
isoforms (Udo et al., 2014). These findings provide evidence of TDG as a transcriptional regulator 
of Hic1 by dual functionality: as a scaffold protein by facilitating the recruitment of TET2 and 
CBP, and a glycosylase by removing 5fC/5caC metabolites generated during HIC1 transcription.   
 
Aim 2: Characterize the role of TDG in vivo (Chapter 3) 
TDG was originally defined as a G:T or G:U mismatch repair protein. Upon discovery of 
TET mediated 5mC oxidation and the subsequent excision of 5fC/5caC by TDG, its role in active 
DNA demethylation was confirmed. It has been established that TDG is a critical component of 
the active DNA demethylation mechanism that functions directly downstream of TETs, and TDG 
is the only known protein in mammalian systems capable of excising 5fC/5caC metabolites. 
However, despite the discovery of the role of TDG in active DNA demethylation, its function in 
post-embryonic development and physiology is unknown. In addition to the constitutive knockout 
of TDG, evidence for the physiological relevance of TDG mediated active DNA demethylation 
was provided by a study on somatic cell reprogramming. Hu et al. (2014) show that TDG, along 
with all TET proteins, is essential for mesenchymal to epithelial transition (MET) during the 
reprogramming of MEFs to induced pluripotent stem cells (Hu et al., 2014). This study showed 
that 5mC, which is present at regulatory regions, undergoes TET mediated oxidation to 5fC/5caC 
during the reprogramming process which are then excised by TDG. Remarkably, the 
reprogramming of MEFs deficient in TDG was completely impaired. This study was important, 
24 
 
since it correlated the generation and excision of 5fC/5caC to transcription and dedifferentiation, 
and provided evidence for TDG dependent active DNA demethylation in a biologically relevant 
process. However, despite these findings, there is no published study that directly addresses the 
role of TDG in post embryonic development in vivo.  
To determine the role of TDG in adult physiology in vivo, we generated Tdgfl/- UBC-
Cre/ERT2+ mice.  In this line, CreERT2 is expressed widely under the control of the ubiquitin C 
(UBC) promoter and is inducible by tamoxifen (TAM) (Chapter 3).  I demonstrate that the 
conditional deletion of Tdg predisposes mice to hepatocellular carcinoma (HCC) through the non-
cirrhotic/non-fibrotic pathway (NCF pathway). Interestingly, a few mice developed 
hepatoblastoma (HB) in addition to HCC.  RNAseq of solid tumors and livers from male mice 
deficient in TDG, depicted a downregulation in metabolism and p75NTR signaling, and 
upregulation of the MAPK and HIPPO signaling pathways. In our mouse model, the onset of HCC 
occurred predominantly in male mice, which display increased obesity and a dysregulation in 
metabolism relevant genes. These findings suggest that TDG potentially regulates the non-
alcoholic fatty liver (NAFLD) pathway of liver cancer. NAFLD is a disease that involves fat 
deposition on the liver due to increased obesity, which is directly related to insulin resistance and 
metabolic syndrome in humans and mice (Kettner et al., 2016; Phillips et al., 2006). Although, a 
direct connection to NAFLD remains to be resolved, my study suggests that a loss of TDG in adult 
mice leads to HCC formation through the NCF-NAFLD pathway.  
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2.1 Introduction 
Derivatives of vitamin A, such as all-trans retinoic acid (ATRA), regulate a complex 
network of genes involved in cell proliferation, differentiation and apoptosis; while, aberrant RA 
signaling has been found in many cancers (Tang & Gudas, 2011). RA mediates its biological 
effects by binding to and activating the retinoic acid receptors (RARα, β) that function primarily 
by forming heterodimers with the Retinoid X receptors (RXRs) (Tang & Gudas, 2011). 
RAR/RXRs belong to the superfamily of nuclear hormone receptors (NRs) that function as ligand-
activated transcription factors to regulate the expression of target genes (Tang & Gudas, 2011). In 
the absence of ligand, or in the presence of specific antagonists, RARs/RXRs actively repress 
transcription by interacting with specific corepressor proteins such as the Nuclear Receptor 
Corepressor (N-CoR) or Silencing Mediator of Retinoic Acid and Thyroid hormone receptor 
(SMRT) (Nagy et al., 1997; Zamir et al., 1996). Agonist binding triggers a specific conformational 
change in the receptor that facilitates the release of corepressor proteins and recruitment of 
coactivator proteins. Many coactivators have been identified for the ligand-bound RAR/RXR 
which provides a highly complex framework for coordinating transcription of target genes. 
Thymine DNA Glycosylase (TDG) catalyzes the first step in a base excision repair pathway 
that removes thymine or uracil from G:T or G:U mismatches. TDG also functions as a coactivator 
and has been implicated in transcriptional control and gene expression by interacting directly with 
various transcription factors such as the RAR, RXR, ER  and TCF4 (Léger et al., 2014; Um et al., 
1998; Tini et al., 2002; Chen et al., 2003b; Jia et al., 2014).  Furthermore, TDG  interacts with the 
lysine acetyltransferases CBP, and its paralog p300, and in vitro studies have revealed that the 
CBP/TDG containing complexes can remove G:T/U mispairs as well as mediate histone 
acetylation (Tini et al., 2002; Léger et al., 2014). 
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More recent studies have established a central role for TDG in epigenetic regulation 
involving DNA demethylation (Cortázar et al., 2011; Cortellino et al., 2011).  DNA methylation 
occurs primarily at cytosine:guanine dinucleotides (CpGs) and is catalyzed by DNA 
methyltransferases (DNMT1, 3a and 3b), which transfer a methyl group from S-
adenosylmethionine (SAM) to the C5 carbon of cytosine (5mC) (Cheng & Blumenthal, 2008). 
Cytosine methylation in this context silences gene expression and is essential for differentiation 
and development (Kafri et al., 1992). DNA methylation is generally regarded as a stable 
modification, but at many regulatory sites DNA methylation is dynamic and is determined by a 
balance between DNA methylation and demethylation events. Two general mechanisms have been 
identified for DNA demethylation. Passive demethylation occurs when newly synthesized DNA 
strands remain unmethylated during successive rounds of DNA replication as a result of reduced 
DNMT activity (Oswald et al., 2000; Kafri et al., 1992; Wu & Zhang, 2010). In contrast, active 
demethylation is a replication independent process that involves the Ten Eleven Translocation 
(TET 1-3) enzymes which oxidize 5mC to 5-hydroxymethylcytosine (5hmC) in a 2-oxoglutarate 
and Fe (II) dependent reaction. Subsequently, 5hmC is then metabolized by TETs into 5-
formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Ito et al., 2011). These oxidized 5mC 
metabolites, 5fC and 5caC, are recognized and removed by TDG. This generates an abasic site 
which is cleaved by AP endonuclease and unmethylated cytosine is then incorporated by DNA 
polymerase (He et al., 2010; Weber et al., 2016).  
 TDG is the only known enzyme that can excise 5fC and 5caC from dsDNA (Globisch et 
al., 2010; He et al., 2010; Ito et al., 2011; Maiti & Drohat, 2011). Furthermore, 5fC/5caC, as well 
as 5hmC, accumulate at many regulatory sites. This suggests that they may function as stable 
modifications to modulate biological activity in addition to their role as demethylation 
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intermediates.  In further support of this function, recent in vitro studies have identified distinct 
proteins that are recruited by 5hmC/5fC/5caC  (Spruijt et al., 2013). Deletion of Tdg in the 
germline is embryonic lethal and leads to DNA hypermethylation with associated defects in the 
expression of various developmentally regulated genes (Cortázar et al., 2011; Cortellino et al., 
2011). Furthermore, it was found that TDG is essential for recruiting the acetyltransferases CBP 
and p300, as well as other histone modifying enzymes, to a subset of target genes and Tdg null ES 
cells fail to differentiate in response to RA (Cortázar et al., 2011).  Importantly, 5fC and 5caC 
levels increase five to ten fold genome wide in Tdg null ES cells (Shen et al., 2014). These findings 
are consistent with the notion that TDG plays a central role in epigenetic stability and methylation 
control and is essential for normal cellular homeostasis. 
In the present study, we have identified the gene Hypermethylated in cancer 1 (Hic1) as 
a novel RAR direct target gene and examined the mechanism of its regulation in MEFs.  HIC1 
expression is often lost in solid cancers and leukemia as a result of DNA hypermethylation of its 
promoter and Hic1 heterologous mice exhibit an increased tumor burden (Mohammad et al., 2011; 
Aggerholm et al., 2006; Chen et al., 2003a; Cheng et al., 2014; Jenal et al., 2010). We show that 
treatment of MEFs with an RA agonist leads to a rapid recruitment of a multi-protein complex 
consisting of RAR/RXR, CBP, TDG, TET1 and TET2 at proximal and distal regions of the Hic1 
gene that encompass novel RA response elements (RARE).  RA treatment also triggers a 3-
dimensional reorganization of chromatin, connecting a proximal 5’ RARE with a distal 3’ RARE. 
Importantly, we show for the first time that the formation of this complex, in response to RA 
correlates with a transient accumulation of 5fC/5caC at the Hic1 promoter that is TDG-dependent.  
This mechanism of action is not restricted to Hic1, as another RAR target gene, Rarβ, is regulated 
in a similar fashion. TDG deletion in adult mice causes hypermethylation of the Hic1 locus with a 
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concomitant loss of HIC1 expression.  Collectively, the present study suggests that active DNA 
demethylation involving TDG is an essential step in Hic1 and Rarβ induction and that deregulation 
of this mechanism may contribute to aberrant epigenetic silencing of these genes in cancer. 
2.2 Results 
2.2.1 Hic1 is an RAR target gene   
Retinoids regulate mesenchymal progenitor (MP) behavior and differentiation (Cash et al., 
1997; Weston et al., 2000; Weston et al., 2002; Hoffman et al., 2006; Dranse et al., 2011).  To 
better understand the molecular basis of RA action in MP cells, we sought to identify relevant 
RAR target genes.  In previous studies, using primary limb mesenchyme (PLM) cultures, treatment 
with bone morphogenetic protein-4 (BMP4) or other BMPs reduced expression of the RA 
synthesis enzyme, Aldh1a2, and this was associated with decreased RA signaling (Hoffman et al., 
2006). Hierarchical clustering was performed on these datasets (Hoffman et al., 2006) to identify 
genes that co-clustered with known RAR target genes, Rarβ and Cyp26a1 (Figure 2.1 A).  Hic1 
was identified as a gene that most tightly co-clustered with Cyp26a1.  Consistent with Hic1 being 
an RA-regulated gene, manipulation of RA signaling in PLM cultures using various 
pharmacological agents, led to changes in expression of Hic1 (Figure 2.1 B).  Treatment with all-
trans retinoic acid (ATRA) or ketoconazole (a broad cytochrome P450 inhibitor that prevents RA 
degradation) increased Hic1 expression.  In contrast, treatment with either BMP4 or a pan-RAR 
antagonist (4310) decreased Hic1 expression.  Congruent with these observations, manipulation 
of RA signaling in embryos with ATRA or 4310, increased and decreased Hic1 expression, 
respectively (Figure 2.1 C).  Deletion of the gene encoding the RA degradative enzyme Cyp26b1 
leads to significant skeletal malformations and increased RA signaling (Dranse et al., 2011; 
Pennimpede  
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Figure 2.  1 Transcriptional activation of the Hic1 gene  
(A) Transcriptional profiling of PLM cultures following treatment with BMP4 (20 ng/ml; 24B and 
72B).  Hierarchical clustering was used to identify genes that co-cluster with known RAR target 
genes, Cyp26a1 and Rarβ.    
(B) Analysis of Hic1 expression in PLM cultures following manipulation of RA signaling with 
ketoconazole (keto), ATRA (100 nM), BMP4 (20 ng/ml) and AGN194310 (100 nM).  
(C) Assessment of Hic1 expression in limb buds following administration of either ATRA (100 
mg/kg) or AGN194310 (4310, 100 mg/kg) for 8h to pregnant dams at embryonic day E12.5.  
(D) RNA analysis of Hic1 in MEFs treated with EC23 for various time periods. MEFs were grown 
to confluency and then treated with EC23 as indicated. RNA was extracted and analyzed by qPCR. 
Significance indicated as *, p < 0.05.  
(E) Western Blot analysis of HIC1 and RARα in MEFs treated with EC23. MEFS were isolated 
and treated with EC23 for various time periods. Proteins were isolated and analyzed by SDS-
PAGE and immunoblotting (IB) was performed using the indicated antibodies.   
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 et al., 2010). Analysis of Hic1 and for comparison Rarβ expression, revealed that both genes were 
significantly upregulated in the Cyp26b1 null background (Figure 2.2 A).  Analysis of RA 
signaling activity in the limbs from transgenic mice containing an RARE-LacZ reporter showed 
that the staining pattern of endogenous Hic1 expression is similar to the staining pattern for LacZ 
activity, especially in those regions flanking the developing digits (Figure 2.2 B).  RA-dependent 
induction of the Hic1 transcript was also observed in embryonic day 14 MEFs treated with the 
photo-stable RAR agonist EC23 (Figure 2.1 E). MEFs contain a mixture of mesenchymal cell 
types and are comparable to the aforementioned utilized PLMs. Under similar conditions, HIC1 
protein expression paralleled that observed for Hic1 mRNA (Figure 2.1 D).  Interestingly, the 
increase in Hic1 expression observed in MEFs was not evident in cancer cell lines. In most tumours 
or cancer cell lines, Hic1 is either silenced or expressed at very low levels, often because of 
hypermethylation of the Hic1 promoter (Jenal et al., 2010, Chen et al., 2003a). For example, in 
MCF7 cells, HIC1 was detected at very low levels but was not upregulated in response to RA 
(Figure 2.3 A). Nevertheless, loss of Hic1 expression was observed when TDG was downregulated 
with siRNA. Together, these observations demonstrate that Hic1 expression is regulated by RA.     
    Previous studies have shown that RAR/RXR proteins form a ternary complex with TDG 
and CBP, or its paralog p300 (Tini et al., 2002). To confirm RAR and CBP as TDG interacting 
partners, we generated a stable HT1080 cell line containing a single copy insertion of FLAG-TDG 
cDNA and utilized a reversible crosslink immunoprecipitation (ReCLIP) technique (Figure 2.3 B).  
Western blotting indicated an upward shift in the TDG band upon RA treatment and crosslinking, 
indicating formation of a TDG complex (Figure 2.3 C). Using this approach, we were able to 
immunoprecipitate both RAR and CBP with FLAG-TDG upon RA treatment (Figure 2.3 D).  
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 The Hic1 locus contains three separate promoters P0, P1 and P2 that give rise to alternative 
exons (1a, 1b and 1c) and a common exon 2 (Figure 2.4 A) (Gue et al., 2004; Guerardel et al., 
2001).  The P0  promoter is associated with exon 1b and based on our analysis and others, only 
exon 1b and 2 are potentially coding (Britschgi et al., 2006). Inspection of the Hic1 promoter 
region revealed a phylogenetically conserved direct repeat 5 (DR5) canonical RARE (proximal 
RARE) approximately 650 bp upstream of the TATA box containing P0 promoter. A second DR5 
(distal RARE) was identified approximately 25 kb downstream of exon 2 (Figure 2.5 A). To assess 
occupancy in response to RA, quantitative ChIP assays were performed using primer sets 
encompassing specific regions of the Hic1 locus. Treatment of MEFs with RA for 90 minutes 
resulted in the recruitment of RAR/ RXR, TDG and CBP to the same region of the promoter 
(Figure 2.4 B-C).  To confirm that TDG, RAR and CBP simultaneously occupy the Hic1 promoter, 
chromatin was immunoprecipitated with an anti-RARα or anti-CBP antibody and the 
immunoprecipitated material was subjected to an additional immunoprecipitation with an anti-
TDG specific antibody (ChIP-reChIP). These results indicate that on the Hic1 promoter, TDG 
associates simultaneously with both RARα and CBP in response to RA. Additionally, as an 
indicator of active transcription, treatment with RA is also associated with the accumulation of 
phosphorylated RNA polymerase II (p-Pol II) and RXRα (Figure 2.4 D). 
Co-transfection assays with various reporter fragments containing regions of the Hic1 
promoter (Guerardel et al., 2001; Gue et al., 2004)  revealed that the promoter fragments containing 
the identified DR5 RARE sequence exhibited increased activity in the presence of constitutively 
active Rarα-VP16 or Rxrα-VP16 (Figure 2.6 A).  The ability of the DR5 RARE to function as an 
RAR-responsive element in a heterologous promoter was also tested.  A multimerized version of 
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Figure 2.  2 Hic1 expression in developing limb buds 
 (A) Analysis of Hic1 and Rarβ expression in Cyp26b1 wild-type and null embryos.  RNA was 
isolated from the proximal limb bud (FL: fore-limb) or distal (paddle region; HL: hind-limb) of 
the limb buds at the indicated times, and gene expression was normalized to 18sRNA.  Significance 
indicated as *, p < 0.05; **, p < 0.01; #, p < 0.001.  
(B) Comparison of Hic1 expression to RARE-LacZ reporter activity in the developing limb buds.  
Whole-mount in situ hybridization was carried out to examine Hic1 expression and corresponding 
RARE-LacZ limb buds were stained with X-gal.   
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Figure 2.  3 HIC1 expression in MCF7 cells and purification of TDG. 
 (A) HIC1 expression in MCF7 breast cancer cells. Cultured MCF7 cells were transfected with 
either control or TDG siRNA. After 48 hr, cells were treated with 1 µM EC23 for 24 hr. Proteins 
were isolated and immunoblotting was performed with the indicated antibodies.  
(B) Western blot of control and FLAG-tagged TDG HT1080 cell lines.  Un-transfected or stably 
transfected FLAG-tagged TDG HT1080 cells were grown to confluency, proteins extracts were 
isolated and immunoblotting (IB) was performed with the indicated antibodies.  
(C) Control and FLAG-TDG stable cell lines were treated with 1 µM RA for 90 min and then 
treated with the Dithiobis[succinimidylpropionate] (DSP) crsosslinker for 30 min. Cells were 
harvested and nuclear proteins isolated. Crosslinks were reversed by the addition of 100 mM DTT. 
Proteins were separated by SDS-PAGE and immunoblotted with TDG antibody (1:3000).  
(D) Immunopurification of TDG complexes. Un-transfected or stably transfected FLAG-tagged 
TDG HT1080 cells were grown to confluency and then treated with 1 µM RA for 90 min and then 
treated with the DSP crosslinker for 30 min.  Proteins were isolated and immunoprecipitations (IP) 
were performed using anti-FLAG Sepharose. The immune complexes were purified using anti-
FLAG Sepharose, crosslinks were reversed and immunoblotting was performed with the 
antibodies shown on the left of the panel. 
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Figure 2.  4 The Hic1 gene is a direct target for the RARα/TDG/CBP complex. 
(A) Schematic of the murine Hic1 locus. The mouse Hic1 upstream regulatory region is shown 
including Hic1 coding and non-coding exons which are shown as solid bars. The various regions 
(RARE, TATA and Gene) are indicated at the bottom of the figure and the proximal RARE is 
found approximately 650 bp upstream of the P0 promoter and is shown as a red triangle.  
(B, C and D) ChIP analysis of the Hic1 locus. MEFs were treated with DMSO (vehicle) or RA (1 
µM) for 90 min and ChIP or sequential ChIP (ChIP-reChIP) assays were performed with the 
indicated antibodies. ChIPs were analyzed by qPCR with primers corresponding to specific regions 
of the Hic1 gene (RARE, TATA or Gene) as indicated at the bottom of each graph. For qPCR IgG 
control values were subtracted from the values using specific antibodies.  
Significance indicated as *, p < 0.05; **, p < 0.01; n=3.  
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the DR5 RARE along with a mutant form was generated and tested, and the wild-type version 
showed a > 20-fold induction when co-transfected with an Rarα-VP16 expression construct 
(Figure 2.6 B).  Collectively, these findings indicate that Hic1 is a direct RAR target gene and that 
RAR, CBP and TDG co-occupy the same region of the Hic 1 promoter following RA treatment 
thus establishing a causal relationship between recruitment and Hic1 expression.  
 A second distal RARE was found approximately 22 kB downstream of the Hic1 locus, 
between introns 14 and 15 of the Smg6 gene which is directly adjacent to Hic1 (Figure 2.5 A).  
ChIP analysis of this site revealed that RARα, CBP and TDG also bind to this region in response 
to RA treatment and that the abundance of these proteins was comparable to that of found on the 
upstream Hic1 P0 promoter (Figure 2.5 B). Based on these results, we speculated that the proximal 
and distal RARE containing regions might physically associate following RA induction. 
Therefore, we developed a series of primers for chromosome conformation capture (3C) and using 
the Hic1 RARE as bait, we assessed the formation of chromatin loops. Remarkably, we find that 
chromatin surrounding the distal RARE within the Smg6 locus undergoes RA dependent looping 
and interacts with the proximal RARE at the Hic1 locus (Figure 2.5 C). This finding suggests that 
recruitment of the RARα complex could potentially facilitate the physical association between 
these sites during Hic1 transcription.  
 
2.2.2 Hic1 undergoes active demethylation in response to RA  
  Hypermethylation of the Hic1 P0 promoter is common in many cancers and contributes 
towards its epigenetic silencing (Britschgi et al., 2008; Aggerholm et al., 2006; Fleuriel et al., 
2009; Britschgi et al., 2006). To assess the DNA methylation status at the Hic1 locus in response 
to RA, initial experiments were performed using bisulfite conversion of the DNA spanning a 1.5 
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kb region (Figure 2.7). Although the overall methylation of the locus decreased by approximately 
25%, the region encompassing the RARE remained unmethylated in untreated and RA-treated 
cells.  However, we identified a 155 bp core CpG-rich region (Chr 11: 75,168,133 – 75,167,978) 
within the Hic1 P0 promoter that undergoes rapid DNA demethylation in response to RA (Figure 
2.8 A). This finding was further validated using both methyl and un-methyl specific PCR (MSP 
and USP, respectively) targeting seven CpG’s within the P0 promoter that show the most 
consistent methylation change in response to RA (Figure 8B). The rapidity of this response in 
MEFs, and the observation that RA stimulation often arrests cells in G1 phase (Tang & Gudas, 
2011; Dimberg and Oberg, 2003), suggests that demethylation involves an active mechanism that 
is not dependent on multiple cell divisions. 
Bisulphite sequencing is unable to distinguish between unmethylated cytosine, 5fC and 
5caC. To identify CpG sites that undergo active demethylation in response to RA, we analyzed the 
Hic1 P0 promoter by M.SssI-assisted bisulphite sequencing (MAB-seq). MAB-seq consists of pre-
treating genomic DNA with the bacterial methyltransferase enzyme M.SssI. The M.SssI treated 
DNA is then treated with bisulphite which will convert 5fC and 5caC to thymine (T). However, 
cytosine (C) is now protected as 5mC. Therefore, sequencing would indicate 5fC and 5caC as T, 
whereas C/5mC/5hmC would be sequenced as C (Wu et al., 2014). The efficiency of M.SssI was 
greater than 98% based on methylation of lambda phage DNA which lacks CpG methylation 
(Figure 2.9).  In control cells, conversion of 5mC to 5fC/5caC was negligible. Remarkably, a 3-
hour treatment with RA resulted in a combined increase of 5fC/5caC to 27.0 % (Figure 2.8 A). In 
contrast, treatment with an RA antagonist (AGN194310) failed to cause a significant accumulation 
of these  
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Figure 2.  5 Formation of RA-dependent chromatin loops at the Hic1 locus 
 (A) Schematic of the murine Hic1 genomic region. The region downstream of Hic1 which 
encompasses the 3’ region of the Smg6 gene is shown. Various exons are shown as solid bars and 
the proximal and distal RAREs are shown as red triangles.  
(B) ChIP analysis of the distal RARE. MEFs were treated with DMSO (vehicle) or 1 µM RA for 
90 min and ChIP assays were performed with the indicated antibodies. ChIPs were analyzed by 
qPCR with primers encompassing the distal RARE region of the Hic1 gene.  
(C) Chromatin looping following RA treatment of MEFs. 3C analysis was carried out as described 
in the Materials and Methods. To detect looping, various combinations of primer pairs were used 
for PCR quantification following enzymatic digestion and verified by gel electrophoresis.  A 
product was detected only when “Bait” and “Z” primers were used indicating that looping only 
occurs in the region containing the two RARES.  
Significance is indicated as *, p < 0.05; **, p < 0.01; #, p < 0.001. n=3. 
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Figure 2.  6 The Hic1 gene contains a bona fide DR5 RARE 
 (A) Identification of a conserved DR5 RARE in Hic1 gene and activation of promoter fragments 
containing this element with constitutively active versions of Rara and Rxra, Rara-VP16 and Rxra-
VP16, respectively.  
(B) multimerization (3) of the Hic1 RARE (1ab), but not a mutant (m1 ab) form confers Rara-
VP16 reporter gene inducibility on a heterologous promoter.   
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metabolites (Figure 2.10 A). Overall, these results suggest that active demethylation at the Hic1 
locus is RA-dependent and involves oxidation of 5mC to 5fC/ 5caC.  
To determine if DNMTs are involved in regulating the Hic1 P0 promoter methylation, we 
investigated the role of de novo methyltransferase DNMT3a. In control cells, DNMT3a is enriched 
at the Hic1 proximal RARE and its abundance is reduced upon RA treatment (Figure 2.8 C). 
Knockdown of DNMT3A using siRNA resulted in demethylation of the P0 promoter (Figure 8D 
and 10B) and upregulation of HIC1 expression in the absence of RA (Figure 2.8 E and 2.10 C). 
MAB-seq analysis indicated a 2.2-fold increase in 5fC/5caC when DNMT3A is knocked down in 
MEFs (Figure 2.10 D). These observations suggest that methylation of the Hic1 P0 promoter is 
dynamic and that DNMT3a is necessary for maintaining RA-dependent transcriptional repression 
of Hic1.  
2.2.3 Recruitment of CBP and active demethylation are TDG dependent 
 The above results indicate that RA-dependent regulation of Hic1 involves the recruitment 
of an RAR/CBP/TDG complex which initiates active demethylation at the P0 promoter of Hic1. 
To examine a more direct requirement for TDG in this mechanism, we generated Tdg f/f; UBC-
cre/ERT2 mice. To drive widespread deletion of Tdg in adult mice, the UBC-CreERT2 line was 
used. These mice contain floxed Tdg alleles along with the ubiquitin C promoter driving the 
tamoxifen (TAM) regulated Cre recombinase. This strategy circumvents embryonic lethality and 
allows conditional deletion of Tdg globally in a temporal manner in response to TAM (Ruzankina 
et al., 2007) (Figure 2.11 A-C). MEFs were prepared from this mouse line and incubated with or 
without TAM prior to treatment with RA. In control cells, Hic1 levels are minimally detectable 
and RA treatment caused a pronounced induction of both protein and mRNA levels (Figure 2.12 
A and 2.12 B). In contrast, when grown in the presence of TAM, Tdg is efficiently deleted and 
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RA-dependent expression of Hic1 is inhibited. TAM pre-treatment had no impact on Hic1 
induction, suggesting that the loss of its expression may be attributable to Tdg deletion (Figure 
2.11 D).  Furthermore, transient overexpression of TDG resulted in partial restoration of HIC1 
expresssion in TDG-deleted MEFs (Figure 2.11 E). 
ChIP analysis confirmed that TDG and CBP are no longer recruited to the Hic1 locus in 
Tdg deleted MEFs (Figure 2.12 C).  We also examined the recruitment of TET1 and TET2 proteins 
as recent studies have shown that they interact physically with TDG and TET1 and TDG co-occupy 
similar genomic regions in ES cells (Weber et al., 2016; Neri et al., 2015). Treatment with RA 
resulted in a dramatic increase in TET2 recruitment to the Hic1 locus that was transient and 
decreased to basal levels by 3 hrs. Importantly, the transient increase in TET2 recruitment was 
inhibited in Tdg knockout MEFS (Figure 2.12 D). The recruitment of TET1 was also increased in 
response to RA. Remarkably, TET1 recruitment was not TDG dependent and increased further in 
TDG knockout MEFs.  This suggests that the mechanism of recruitment for TET1 and TET2 is 
different. To assess if TDG is required for RA dependent active DNA demethylation of the Hic1 
P0 promoter, we performed MAB-seq analysis in wild-type and Tdg deleted MEFs following a 3-
hour RA treatment (Figure 2.12 E).  In untreated cells, a 4-6-fold increase in 5fC/5caC was 
observed upon Tdg deletion. This is consistent with previous models showing that under steady 
state conditions, loss of Tdg causes an accumulation of 5mC derivatives (Kohli & Zhang, 2013; 
Shen et al., 2013; Ito et al., 2011). Surprisingly, the accumulation of 5fC/5caC was not significantly 
different between wild-type and Tdg knockout MEFs upon RA treatment, suggesting that the RA 
driven conversion of 5mC to 5fC/5caC is not evident upon Tdg deletion at this time point.   
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Figure 2.  7 Bisulfite sequencing of the Hic1 locus. 
(A) bisulfite sequencing of 36 CpG sites surrounding the RARE at Hic1 locus reveals a 2.7 % 
methylation in the untreated state.  
(B) Bisulfite sequencing of 58 CpG sites downstream of the RARE reveals RA dependent DNA 
demethylation at the locus, and particularly within the P0 promoter. 
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Figure 2.  8 RA dependent active demethylation at the Hic1 promoter. 
(A) DNA methylation analysis of the Hic1 P0 promoter. MEFs were treated with DMSO (vehicle) 
or RA for 3 hrs.  DNA was extracted, and either the DNA was treated with bisulphite alone and 
then sequenced (Bisulfite Sequencing), or the isolated DNA was treated sequentially with M.SssI 
and then bisulfite (MAB-seq) followed by sequencing of the P0 promoter region of the Hic1 gene. 
Shown are a representative result from three independent experiments.  
(B) Samples were treated with bisulfite and then analyzed by PCR using specific primers 
recognizing the methylated (MSP) or unmethylated (USP) region contained within the P0 
promoter.  
(C) Loss of DNMT3A occupancy at the proximal RARE. MEFs were treated with DMSO (vehicle) 
or 1 µM RA for 90 min and ChIP assays were performed with a DNMT3A antibody. ChIPs were 
analyzed by qPCR with primers corresponding to the proximal RARE region of the Hic1 gene.  
(D) Methylation-specific PCR of the Hic1 promoter. MEFs were transfected with the indicated 
siRNAs. Cells were then treated with DMSO (vehicle) or RA for 90 min. DNA was extracted and 
the core CpG region of the Hic1 P0 promoter was analyzed by methylation-specific PCR using 
primers recognizing the methylated sequence.  
(E) Western blot analysis of HIC1.  MEFs were transfected with the indicated siRNAs. Proteins 
were extracted and immunoblotting (IB) was performed with the indicated antibodies.  
*, p < 0.05; **, p < 0.01; #, p < 0.001; NS: not significant. 
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Figure 2.  9 Optimization of the M.SssI enzyme for the methylase-assisted bisulfite 
sequencing technique. 
Treatment of the λ DNA, which completely lacks DNA methylation, with the M. SssI methylase 
enzyme leads to efficient methylation of DNA.  
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Figure 2.  10 MABseq analysis at the Hic1 P0 promoter 
 (A) Treatment of MEFs with an RA antagonist. MEFs were treated with vehicle (DMSO) or 1 
µM AGN194310 for 3 hrs and then MABseq was performed as described in Materials and 
Methods. 
(B) Methylation-specific PCR (MSP) of the Hic1 P0 promoter. MEFs were transfected with the 
indicated siRNAs.  DNA was extracted and the core CpG region of the Hic1 P0 promoter was 
analyzed by MSP using primers recognizing the methylated sequence.  Region 8 bisulfite 
sequencing primers (i.e. contain no CpG sites) were used for normalizing the DNA loading.  
(C) MEFs were transfected with control siRNA or siRNA targeting DNMT3A.  After 48 hrs, 
proteins were extracted and immunoblotting was performed with the indicated antibodies. 
(D) MEFs were transfected with siControl or siDNMT3A, and after 48 hrs DNA was isolated. 
MAB-seq was then performed by treating the isolated DNA sequentially with M.SssI and then 
bisulphite as described in Materials and Methods.  The P0 promoter region of the Hic1 gene was 
then analyzed by conventional sequencing. 
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Therefore, we performed MAB-seq at different time points following RA treatment (Figure 2.12 
F). In the presence of TDG, 5fC/5caC intermediates accumulate in response to RA and reach a 
peak of 22% at 6 hours (Figure 2.12 F). This finding shows that the accumulation of 5mC 
derivatives in response to RA is not significantly affected upon Tdg deletion, but their subsequent 
removal is blocked.   
We also examined the accumulation of 5fC/5caC at the Rarβ gene. Like Hic1, the Rarβ 
gene contains a consensus RARE upstream of a CpG island within its promoter and has been 
previously shown to be an RAR target that is induced in response to RA (May et al., 2010).  
Treatment with RA for 90 minutes resulted in the recruitment of TDG, TET1 and 2 to the Rarα 
RARE within its promoter (Figure 2.13 A). Importantly, MAB-seq analysis resulted in a six-fold 
increase in 5fC/5caC in response to 3 hr RA treatment (Figure 2.13 B).  
Collectively, these findings suggest that Tdg is required for promoting RAR complex 
stability as well as active DNA demethylation at the Hic1 locus, as well as other RAR-dependent 
genes.  
 
2.2.4 Tdg deletion in vivo causes Hic1 silencing 
Based on the observation that TDG plays a role in RA-dependent Hic1 regulation, we 
speculated that Tdg deletion in mice would also affect the induction of HIC1 protein in vivo. In 
order to test the efficiency of cre-ERT2 recombinase activation, adult UBC-cre/ERT2;Tdgfl/fl and 
Tdgfl/fl mice (8 weeks) were treated once/day for 5 days with TAM by intraperitoneal injection. 
After 4 weeks, post-TAM treatment various tissues were isolated and TDG expression was 
examined.  TDG expression was reduced in all tissues examined (Figure 2.11 F). In tissues, such 
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as spleen and thymus there was a dramatic loss in HIC1 expression (Figure 2.14 A and data not 
shown).  Importantly, the Hic1 gene from UBC-cre/ERT2; Tdgfl/fl mice is silenced and the Hic1 P0 
promoter is entirely hypermethylated compared to wild-type mice (Figure 2.14 B).   
These results strongly suggest that in the absence of active demethylation is disrupted and 
the Hic1 locus develops a vulnerability to DNA hypermethylation  as has been found in many 
cancers. 
 
2. 3 Discussion 
The transcriptional repressor HIC1 is located at 17p13.3, a region that is often deleted or 
hypermethylated (and silenced) in human cancers (Guerardel et al., 2001; Fleuriel et al., 2009). 
Hypermethylation of the HIC1 locus has been frequently observed in a variety of tumors, including 
breast, brain, and colon cancers.  Consistent with these observations, Hic1 heterologous mice 
exhibit an increased tumor burden and develop many different malignant tumors, including a 
predominance of epithelial cancers, sarcomas and lymphomas (Mohammad et al., 2011). 
Importantly, bisulphite sequencing of all of these tumors indicates that the remaining wild-type 
Hic1 allele undergoes epigenetic silencing marked by DNA methylation (Briggs et al., 2008). 
Despite the importance of HIC1 as a tumor suppressor, the mechanism regulating its expression is 
poorly understood. Previous work has shown that HIC1 is induced by RA during granulocyte 
differentiation (Britschgi et al., 2008). Herein we establish an important link between RA signaling 
and transcriptional activation of the Hic1 gene in vitro and in vivo. We have found that 
transcriptional silencing of Hic1 is mediated, in part, by DNMT3a, which is required to maintain 
the methylation status of the P0 promoter. We show for the first time that activation of the RAR/  
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Figure 2.  11 Conditional deletion of TDG 
(A) Schematic diagram of the mouse TDG genomic structure showing the location of the loxp sites 
(B– C) Treatment of Tdg fl/fl and Tdg fl/fl; UB-cre/ERT2+ MEFs with 100 nM 4-hydroxytamoxifen 
causes an efficient recombination of Tdg exon 2 and loss of TDG at the protein level.  
(D) The treatment of MEFs with 100 nM 4-hydroxytamoxifen does not affect the expression of 
HIC1 by EC23.  
(E) Re-introduction of TDG in Tdg KO MEFs results in partial rescue of HIC1 expression. The 
cre-ERT2 mediated depletion of TDG protein was performed using 4-OH-TAM as described in 
Material and Methods. Tdg KO MEFs were transfected with a plasmid containing FLAG-TDG 
under the control of the CMV promoter and allowed to grow for 2 days prior to treatment with 
EC23. The lysates were prepared 24 hour following EC23 treatment and western blot performed 
using the indicated antibodies (TDG, 3000X; Vinculin, 10000X; mHIC1, 5000X).  
(F) Conditional deletion of TDG in adult mice. Intraperitoneal injection of 15 mg tamoxifen over 
a 5-day period in adult (8 weeks old) Tdg fl/fl and Tdg fl/fl; UB-cre/ERT2+ mice reveals an efficient 
knockdown of TDG at the protein level. Tissues were harvested from these mice 4 weeks after the 
last tamoxifen injection, protein extracts were prepared and analyzed by immunoblotting using 
anti-TDG antibody (1:3000).  
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Figure 2.  12 Transcriptional activation of Hic1 in response to RA is TDG dependent.  
(A) MEFs were incubated in the presence or absence of 4-hydroxytamoxifen (4-OH-TAM) for 48 
hrs. and then treated with EC23 for 24 hrs. Proteins were isolated and immunoblotting (IB) was 
performed with the indicated antibodies.  
(B) MEFs were treated with DMSO (vehicle) or 1 µM RA. RNA was extracted and analyzed by 
qPCR.  
(C) Control or Tdg knockout (KO) MEFs were treated as described in (B) and ChIPs were 
performed using either a TDG (left) or CBP-specific antibody (right). Products were analyzed by 
qPCR with primers encompassing the Hic1 P0 promoter.  
(D) Wildtype and Tdg knockout MEFs were treated with DMSO (vehicle) or 1 µM RA for various 
time periods as shown. ChIPs were performed using either a TET2 or TET1 specific antibody. 
Products were analyzed by qPCR with primers encompassing the Hic1 P0 promoter.  
(E) Wildtype and Tdg knockout MEFs were treated with DMSO (vehicle) or 1 µM  RA for 3 hrs. 
DNA was isolated and M.SssI-assisted bisulphite sequencing (MAB-seq) was performed by 
treating the isolated DNA sequentially with M.SssI and then bisulphite as described in Materials 
and Methods.  The P0 promoter region of the Hic1 gene was then analyzed by conventional sanger 
sequencing.  
(F) Time course of 5fC/5caC accumulation in MEFs. Wildtype and Tdg knockout MEFs were 
treated with DMSO (vehicle) or 1 µM RA. DNA was isolated and MAB-seq was performed as 
described in (E). The P0 promoter region of the Hic1 gene was then analyzed by conventional 
sanger sequencing. Where indicated *, p < 0.05; **, p < 0.01, NS: not significant.  
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Figure 2.  13 RA-dependent active demethylation of the Rarβ gene 
(A) ChIP analysis of the Rarβ promoter. In the schematic representation of Rarβ gene, the major 
exon is shown as a solid bar and the RARE is shown as a red triangle upstream of a CpG island.  
MEFs were treated with DMSO (vehicle) or 1 µM RA for 90 min and ChIP assays were performed 
with the indicated antibodies. ChIPs were analyzed by qPCR with primers encompassing the 
RARE region of the Rarβ promoter.   
(B) RA dependent active demethylation of the Rarβ gene. MEFs were treated with DMSO 
(vehicle) or RA for 3hrs. DNA was isolated and MAB-seq was performed by treating the isolated 
DNA sequentially with M.SssI and then bisulphite as described in Materials and Methods.  The 
CpG island encompassing the RARE, promoter and exonic regions of the Rarβ gene were then 
sequenced 
Where indicated *, p < 0.05; **, p < 0.01, NS: not significant.  
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RXRα pathway displaces DNMT3A, triggering active demethylation of the P0 promoter.  
Furthermore, this involves recruitment of TET proteins and accumulation of 5fC/5caC metabolites. 
Importantly, we have generated a new conditional mouse model to demonstrate that the expression 
of Hic1, and accumulation and subsequent removal of 5fC/5caC, are TDG dependent.  Loss of 
TDG in vivo leads to Hic1 silencing that correlates with DNA hypermethylation of the Hic1 
promoter. These results highlight the importance of TDG in signal dependent DNA 
methylation/demethylation events and highlight an important role for RAR/RXR in mediating 
targetted active DNA demethylation 
 
2.3.1 Involvement of 5fC/5caC in RA dependent Active Demethylation  
MAB-seq is a novel technique that allows the quantitative mapping of both 5fC and 5caC 
and is ideal for studying DNA methylation dynamics at specific loci because it does not require 
subtractive analysis of two sequences (Neri et al., 2015). Our data indicates that in wild-type MEFs, 
the accumulation of 5fC/5caC metabolites at the Hic1 P0 promoter is time dependent, peaking at 
approximately 90 minutes after RA treatment and then declining to near basal levels by 6 hr. In 
contrast, upon the conditional deletion of Tdg, 5fC/5caC metabolites continue to accumulate 
suggesting that their excision rate is decreased with a concomitant loss of DNA demethylation at 
the locus and downregulation of the Hic1 transcript.  TET2 is also recruited to the Hic1 promoter 
upon RA treatment and correlates with a loss of DNA methylation and upregulation of 5fC/5caC 
at the P0 promoter. In the absence of TDG, accumulation of TET2 is diminished suggesting that 
TDG is required for recruitment and anchoring of TET2 at sites of active DNA demethylation 
(Muller et al., 2014). In contrast, TET1 recruitment is maintained and its levels increase further  
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Figure 2.  14 Hic1 expression is TDG dependent in vivo 
(A) Tdffl/fl  (wild-type) or UBC-CreERT2; Tdgfl/fl (Tdg KO) mice were injected with 4-OH-TAM 
for 5 days and allowed to recover for 2 weeks. Spleen tissues were removed, and proteins were 
isolated and analyzed by immunoblotting with the indicated antibodies.  
(B) Spleens from Tdgfl/fl  (control) or UBC-creERT2; Tdgfl/fl mice were removed, and DNA isolated 
and analyzed by bisulphite sequencing as described in Materials and Methods. The mouse B cell-
specific gene product (MB-1) was used as control. The analysis is representative of 3 independent 
experiments.  
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when TDG is deleted. The reason for these differences between TET1 and TET2 are not entirely 
clear. Although TET isoforms 1 and 2 are capable of oxidizing 5mC, into 5hmC, 5fC and 5caC, 
they differ structurally in terms of their domain architecture as well as tissue specificity. TET1 
contains an N-terminal CXXC domain which is notably absent in TET2. The CXXC domain is a 
novel DNA binding motif that binds dinucleotide CpGs as wells as 5caC with high affinity 
suggesting that it is most likely involved in targeting the enzyme to specific genomic regions (Jin 
et al., 2016). This could explain why 5fC/5caC continue to accumulate despite the loss of TET2. 
Overall, these findings indicate that TDG functions downstream of 5fC/ 5caC formation and that 
its dual catalytic and scaffolding activities are essential for Hic1 transcription. 
MABseq has previously shown that 5fC/5caC metabolites become enriched near the 
transcription start sites (TSS) of many actively transcribed genes in ES cells and in some contexts, 
may serve as an indicator of 5mC demethylation (Neri et al., 2015). However, recent studies have 
identified additional functions for 5fC/5caC suggesting a potential role of these cytosine 
derivatives beyond transient intermediates. Reader proteins that specifically bind 5fC/5caC in vitro 
have been identified (Spruijt et al., 2013). Furthermore, the introduction of 5fC/5caC within a 
dsDNA template causes transcriptional pausing and interferes with transcription by RNA pol II 
during transcriptional elongation in vitro (Wang et al., 2015). This suggests that 5fC/5caC 
metabolites may be important for fine tuning the elongation of specific genes and thereby affect 
gene expression. Furthermore, TDG interacts with RARα, as well as other coregulators such as 
CBP/p300.  It is conceivable that TDG bound 5fC/5caC may play a functional role in targeting 
proteins in order to modulate transcriptional elongation. 
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2.3.2 Accumulation of 5fC/5caC may predispose DNA to subsequent hypermethylation 
Conditional deletion of Tdg in vivo causes a loss of HIC1 expression.  Remarkably, 
bisulphite analysis in spleen from Tdg knockout mice indicated that the Hic1 P0 promoter is 
entirely hypermethylated in vivo and HIC1 is not expressed. This contrasts to our finding in MEFs 
showing that Tdg deletion causes 5fC/5caC metabolites to accumulate in a time-dependent manner.  
This suggests that Tdg deletion may cause an accumulation of 5fC/5caC, and in combination with 
the loss of TDG scaffolding activity, predisposes this site to subsequent DNA hypermethylation. 
Furthermore, 5fC/5caC cannot be maintained by DNMT1, hence, they would undergo passive 
dilution upon subsequent cell divisions. This would provide access to de novo DNA 
methyltransferases for subsequent hypermethylation of these sites.  This model is supported by a 
recent study indicating that sites of 5fC accumulation upon Tdg knockdown are specifically 
targeted for DNA hypermethylation following differentiation (Raiber et al., 2012).  
 
2.3.3 Implications of Active Demethylation in Retinoic Acid Signaling Events 
 Although TDG has been shown to function as a scaffolding protein at several RA 
dependent genes, our study represents the first demonstration that RA triggers active DNA 
demethylation and has important implications to our general understanding of the function of the 
RA signaling pathway. Previous studies have indicated that DNA methylation is lost upon the 
stimulation of certain RA responsive genes, such as Rarβ and Cyp2A1 (Le May et al., 2010).  
However, the involvement of TETs and the generation of 5mC oxidation products was not 
established. The finding that Hic1 and Rarβ genes are regulated by a similar mechanism represents 
the first line of evidence for retinoid signaling in 5mC oxidation by TET/TDG pathway involving 
a loss of 5mC and generation of 5fC/5caC metabolites.  
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Retinoid signaling is known to be compromised in many cancers, and DNA 
hypermethylation of retinoid target genes plays a major role in loss of sensitivity to RA (Farias et 
al., 2002; Narayan et al., 2003).   Furthermore, retinoids often exhibit anti-proliferative activities 
and in many systems RA-induced growth arrest is associated with increased cell differentiation or 
apoptosis (Wales et al., 1995). Hic1 is hypermethylated in a large number of diverse cancers, and 
it will be of interest to determine if aberrant RA signaling at least in part underlies silencing of 
HIC1 in cancer.   In this regard, therapeutic strategies aimed at re-activating HIC1 expression may 
prove useful for modifying tumour initiation, growth and progression.     
Herein, we have identified Hic1 as a novel RA target gene and show that active DNA 
demethylation is an essential step in gene transcription of Hic1 in response to RA. We find that 
this process requires RA-dependent 5mC oxidation, which is mediated by TET proteins. Our data 
suggests that TDG facilitates 5fC / 5caC turnover in MEFs, and that deletion of Tdg can predispose 
genes to hypermethylation in vivo.  These findings highlight the expanding role of TDG and active 
demethylation in epigenetic regulation, and further identify important molecular mechanisms that 
may be targeted by oncogenic processes. 
 
2.4 Experimental Procedures  
2.4.1 Mouse Protocol  
All mouse experiments were done in compliance with the Institutional Animal Care and 
Use Committee guidelines at London Regional Cancer Center at Western University and the 
University of British Columbia. For the conditional deletion of Tdg, Tdg fl/fl mice were bred with 
UBC-cre/ERT2 mice to generate UBC-cre/ERT2; Tdg fl/fl mice.  Subsequently, adult (8 weeks old) 
UBC-cre/ERT2; Tdg fl/fl and litter matched Tdg fl/fl controls were intraperitoneally injected with 3 
81 
 
mg TAM daily for 5 days. To assess cre-ERT2 efficiency and HIC1 expression, the mice were 
euthanized 4 weeks after TAM injections, tissues were harvested, lysed using RIPA buffer and 
western blotting performed using anti-TDG-antibody. 
 
2.4.2 Cell Culture and Transfection 
Embryonic age (E) 17.5 MEFs were isolated from Tdg fl/fl or Tdg fl/fl; UB-cre/ERT2+ mice 
as previously described (Jozefczuk et al. 2012). To induce deletion, the Tdg fl/fl UBC-cre/ERT2 
MEFs were treated with 100 nM 4-hydroxytamoxifen for 48 hours, and then incubated with 
DMEM for 48 hours prior to experimentation. For experiments involving treatments, cells were 
grown to confluency in charcoal stripped supplemented media for 72 hours, before being 
challenged with DMSO (Vehicle), 1 μM RA, EC23, or the RAR antagonist AGN194310 (4310).  
Primary limb mesenchymal cultures (PLM) were established as previously described 
(Underhill et al., 2014) and treated with ketoconazole (2 µM), BMP4 (20 ng/ml), 4310 (100 nM), 
ATRA (100 nM) or vehicle control (DMSO).   PLM cultures from Cyp26b1 wild-type and null 
embryos were generated as previously described (Dranse et al. 2011).  For transfection, reporter 
plasmids containing various portions of the Hic1 promoter were transfected into PLM cultures as 
previously described (Underhill et al., 2014) along with expression plasmids for Rarα-VP16 and 
Rxra-VP16 (Underhill et al. 1994).  To normalize for transfection efficiency, all transfections 
included the control vector phRL.  Forty-eight hrs post transfection, cultures were lysed in passive 
lysis buffer and firefly renilla luciferase was measured using the dual luciferase reporter assay 
system (Promega) according to the manufacturer’s guidelines.  Luciferase activity is shown as 
relative light units (RLU) which is generated by firefly luciferase activity/ renilla luciferase 
activity.   
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For siRNA mediated knockdowns, the cells were incubated with PepMute (SignaGen 
laboratories) as per manufacturer guidelines. 20 µM concentration of respective siRNA’s were 
utilized for transient knockdowns. The cells were incubated with siRNA and PePmute reagent for 
48 hours and then media was changed, or lysates prepared depending on the experiment.  
  
2.4.3 RNA extraction, reverse transcription polymerase chain reaction and real-time 
polymerase chain reaction  
Total RNA was extracted using an RNA extraction kit (Qiagen). cDNA was synthesized 
using the Applied Biosystems Reverse Transcription Kit . The mRNA was reverse-transcribed for 
10 min at 25 oC, followed by incubation at 37o C.  Quantitative PCRs (qPCRs) were performed 
using a Taqman or SYBR Green-detection system (Applied Biosystems) and transcript abundance 
was normalized to 18s rRNA.  
 
2.4.4 Chromatin Immunoprecipitation (ChIP) 
 ChIP and ChIP-reChIP assays were performed as previously described (Thillainadesan et 
al. 2012).  
 
2.4.5 Bisulfite sequencing and quantitative PCR 
MEFs were grown to approximately 90 % confluency in charcoal stripped conditions and 
then treated with 1 µM RA for 3 hours. Cells were then harvested and DNA was extracted using 
the Sigma genomic DNA extraction kit. Approximately 1 μg of DNA was used for bisulfite 
conversion using the Epitect Bisulphite Kit (Qiagen) according to the manufacturer’s instructions. 
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For methyl-specific or un-methyl specific PCR, the bisulfite converted DNA was used in 
conjunction with methyl-specific or un-methyl specific primers, respectively, and SYBR Green 
Master Mix was used for qPCR.  
 
2.4.6 MAB-SEQ 
Mab-seq was performed as described (Wu et al. 2014). Briefly, 1 μg of genomic DNA was 
treated with 4 U of M.SssI (NEB) in a 20 μl reaction containing 160 mM SAM for 2 hrs. The 
reaction was then supplemented with an additional 4 U of M.SssI and 160 mM SAM for another 4 
hours. DNA was purified by Phenyl: chloroform: isoamyl (PCI) followed by ethanol precipitation 
after each round of treatment. This was repeated an additional three times. The methylated DNA 
template was then bisulfite converted, and specific regions were PCR amplified, cloned into TA 
vector and sequenced.  
 
2.4.7 Generation of a FLAG-TDG expressing HT1080 cell line 
The FLAG-TDG expressing HT1080 cell line was generated using the FLP-IN system 
(Thermo Fisher) per the manufacturer’s instructions. An HT1080 fibrosarcoma cell line containing 
a single integrated Flp Recombination Target (Frt) site was grown to roughly 70–80 % confluency. 
The cells were then co-transfected with a plasmid containing a Flag-TDG cDNA driven by a CMV 
promoter and containing an Frt site, and a second plasmid containing FLP recombinase cDNA, 
respectively. After 48 hours, HT1080 cells were grown in the presence of 175 µg/ml hygromycin 
containing media to select for the cells with integration of the FLAG-TDG gene. The resulting 
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resistant colonies were expanded, extracts prepared and assessed for expression of the FLAG-TDG 
protein by immunoblotting using anti-FLAG antibody (1:300) or anti-TDG antibody (1:3000). 
 
2.4.8 Reversible Crosslink Immunoprecipitation (ReCLIP) Protocol 
 The ReCLIP protocol was performed as previously described (Smith et al. 2011). Briefly 
cells were incubated with 20 mM DSP in PBS for 30 minutes at room temperature. The reaction 
was quenched with a 125 mM glycine solution and cell extracts were prepared with a lysis buffer 
consisting of 50 mM Tris (pH 8.0), 0.3M KCl, 0.1% NP40 and 0.5 mM EDTA. 
Immunoprecipitations were then performed using anti-FLAG Sepharose per the manufacturer’s 
instructions (Sigma). To reverse the crosslinks, the protein lysates were incubated with 100 mM 
DTT for 15 minutes at 100oC prior to western blotting  
 
2.4.9 Chromosome Conformational Capture (3C) Assay 
The 3C assay ws performed as previously described with minor modifications (Zuchegna 
et al. 2014). Briefly, 2.5 x106 cells were crosslinked using 1 % formaldehyde in PBS buffer at 
room temperature with shaking. The reaction was quenched with 125 mM glycine, and the fixed 
cells were washed twice and then harvested using 1 ml of ice cold PBS. Harvested cells were spun 
down at 250g for 10 minutes and then incubated in lysis buffer I (10 mM Tris-HCl [pH 8.0], 10 
mM NaCl, 0.2 % NP40, and protease inhibitors), homogenized, and centrifuged at 450g for 15 
minutes. The pelleted nuclei were washed using buffer I (1x restriction digest buffer), and then re-
suspended in 1 x restriction buffer. SDS was added to a final concentration of 0.1% and the cells 
were incubated at 65 oC for 10 minutes with shaking to lyse the nuclei. Triton X-100 was added to 
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the final concentration of 1 % to quench the SDS and then 100 U of NcoI was added and incubated 
overnight at 37 oC with rotation. SDS was added to a concentration of 1 % and incubated at 65 oC 
for 30 minutes with shaking, and then placed on ice and 1 ml of 1x ligation buffer containing 1% 
Triton X-100 was added. The reactions were equilibrated to 16 oC and 50 U of T4 DNA ligase was 
added and incubated overnight. The following day, 300 μg of proteinase K was added to each 
reaction and then incubated at 65 oC overnight. The DNA was then purified using phenol: 
chloroform: isoymyl (PCI) and ethanol precipitated. Samples were dissolved in 30 μl of Tris-
EDTA buffer (pH 8.0). The efficiency of digestion was assessed by amplifying a fragment 
spanning two NcoI (uncut) sites in different 3C DNA preparations.  
 
2.4.10 Statistical Analysis 
The data represented in ChIP, ChIP-reChIP, qPCR (for mRNA expression), methyl-
specific qPCR and 3C figures are representative of at least three independent biological replicates. 
For the 3C experiment, the data from gel electrophoresis was assessed by the ImageJ software, 
using the untreated lane for normalization. All western blots are representative of at least duplicate 
experiments. Statistical analyses were performed using GraphPad Prism 5.0, employing the 
Student’s t-test (2 groups), or ANOVA with Tukey post-hoc (3 groups or more). All p-values over 
0.05 were deemed not significant.  Significance is indicated as follows: *, p < 0.05; **, p < 0.01; 
#, p < 0.001; NS, not significant.  
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Table 2. 1 List of antibodies used in this chapter 
Antibody Species Company Catalogue No. 
TDG mouse Rabbit Homemade N/A 
RARα Rabbit Santa Cruz sc-551 
CBP Rabbit Santa Cruz sc-369 
HIC1 mouse Rabbit Homemade N/A 
RNA pol II Rabbit Abcam ab5131 
RXRα Rabbit Santa Cruz sc-553 
Vinculin Mouse Sigma V9264 
DNMT3a Rabbit Santa Cruz sc-20703 
Tubulin Mouse Sigma T 5168 
TET1 Rabbit Active Motif 61443 
TET2 Rabbit Abcam ab124297 
TDG human Rabbit Pierce PA5-29140 
HIC1 human Rabbit Sigma HPA043372 
RARβ Rabbit Santa Cruz sc-552 
Anti-Flag Mouse Sigma F3165 
 
Table 2. 2 List of ChIP primers used in this chapter 
Primer Name Forward Reverse 
RARE 5’-ATCTGGTCCTCGTGCGCC-
3‘ 
5’-
CCGAGTCCTCTAGGGAAGACA-
3’ 
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TATA 5’-
TCTTGCTCCCGTCTTCCTTA-
3‘ 
5’-CATTCAGGGCCGAGAAGTT-
3‘ 
Gene Body 5’-
GGTGCATGACAACCTGCTAA-
3‘ 
5’-
GGCCTCAACACTGTCAGTCA-3‘ 
Distal RARE 5’-TGTCCTTGCCTGCTCTGAC-
3’ 
5’-CTGCCCACTTCTTCCTTTTC-
3’ 
RARβ RARE 5’-
GGGAGTTTTTAAGCGCTGTG-
3’ 
5’-CGGAGCAGCTCACTTCCTAC 
-3’ 
 
Table 2. 3 List of 3C primers used in this chapter 
Primer Name Sequence 
Bait 5’-CGCTTTCCGCACACTCTTATCT-
3‘ 
B 5’-
GCTACTCAGAGCTACTTTCCCAG-3‘ 
Z 5’-
TCTCTCCACCAGGCTTATTCCTCTC-
3‘ 
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Table 2. 4 List of bisulfite sequencing primers used in this chapter 
Primer 
Name 
Forward Reverse 
RARE 5’-GGGGTTTTAAGTGTTTTTTTTAGAG-3‘ 5’-CCAATTCCTCCTCTAAACCC -3’ 
Region 
5 
5’-GTTTTATGTTTTTGATTAGTTGAGG-3‘ 5’-TTTAACAAATTATCATACACCACC-
3‘ 
Region 
4  
5’-GTTTTTTGTTTTTTTATTTGGG-3‘ 5’-
CCTCAACTAATCAAAAACATAAAAC-
3‘ 
Region 
6 
5’-GTTATTAGGTTGTTGAAATTGGG -3’ 5’-CCCAAATAAAAAAACAAAAAAC -3’ 
Region 
8 
5’-GAGTTGGGGAAGAGATGTGGAG -3’ 5’-CCAACCCCAAATACTCCTAAACAC -
3’ 
RARβ 5’-
GTTAGATTGGTTGGGTTATTTGAAGGTTAG 
-3’ 
5’-
CATCCATACAATCAAACATAATCTCTC 
-3’ 
MSP * 5’-TTCGGGTCGGGTCGGTCG -3’ 5’-AAAACGCCTCCCGCCTCG -3’ 
USP ** 5’-TTGGGTTGGGTTGGTTGG -3’ 5’-AAAACACCTCCCACCTCA -3’ 
Lambda 
DNA  
5’-TTTGGGTTATGTAAGTTGATTTTATG -3’ 5’- CACCCTACTTACTAAAATTTACACC 
-3’ 
MB-1 5’-GGGATTAGTGGTGATGAATT -3’ 5’-
CTCTAAAAACTTCTAAACCCCCTAAC -
3’ 
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* MSP: Methyl-specific PCR 
** USP: Un-methyl specific PCR 
 
Table 2. 5 Sequence of siRNA’s used for transient knockdowns used in this chapter 
Target Type Species siRNA sequence Company Catalogue 
No.  
 
TDG 
 
Pooled 
 
Human and 
mouse 
5’-GCAAGGAUCUGUCUAGUAA 
-3’ 
5’-CAAAGAAGAUGGCUGUUA -
3’ 
5’-GAGUAAAGGUUAAGAACUU 
-3’ 
5’-GAAGUGCAGUAUACAUUUG 
-3’ 
 
Dharmacon 
 
M-040666-
01-0050 
DNMT3a Pooled Human and 
Mouse 
Not stated Santa Cruz sc-37757 
siControl Pooled Human and 
Mouse 
Not stated Dharmacon D-001206-
13 
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Chapter 3:  Thymine DNA Glycosylase is a tumor suppressor of liver malignancies 
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3.1 Introduction 
 
The methylation of cytosine at 5th carbon (5mC) is important in a variety of biological 
processes including gene regulation, genomic imprinting, X chromosome inactivation and the 
suppression of mobile genetic elements (Bestor and Bourc’his, 2004; Jaenisch and Bird, 2003). 
This mark is faithfully reproduced over successive replication cycles by the maintenance DNA 
methyltransferase 1 (DNMT1) protein, whereas, the de novo DNMTs (DNMT2, DNMT3a and 
DNMT3b) can deposit novel methylation marks in a cell cycle independent manner (Wu and 
Zhang, 2017). Recent studies have demonstrated that DNA methylation is dynamic and can be 
removed via both passive and active processes. In passive DNA demethylation, the methylated 
DNA is diluted over successive replication cycles resulting from deactivation of the 5mC 
maintenance machinery. 5mC can also be metabolized and actively demethylated in response to 
specific signals, independent of DNA replication. This process involves the Ten eleven 
translocation (TET1-3) family of proteins as well as Thymine DNA Glycosylase (TDG).   
 In active DNA demethylation, the TET proteins recognize and successively oxidize 5mC 
to 5-hydroxyethylcytosine (5-hmC), and then to 5-formylcytosine (5-fC) and 5-carboxylcytosine 
(5caC) (Hassan et al., 2017; He et al., 2010; Ito et al., 2011; Piccolo and Fisher, 2014). The BER 
protein Thymine DNA Glycosylase (TDG) plays an essential role in this process by catalyzing the 
initial removal of 5-fC and 5-caC metabolites (Ito et al., 2011). This forms an apurinic (AP) site 
and the combined actions of APE1, DNA pol β and XRCC1- DNA ligase IIIα complex 
subsequently replace the AP site with an unmethylated cytosine.  Interestingly, knockout studies 
demonstrate that TDG is the only glycosylase in mammalian system that is necessary for 
embryonic development (Cortazar et al, 2011; Cortellino et al., 2011)  Knockout of TDG in mice 
leads to embryonic lethality at a time point when the genome is undergoing epigenetic 
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reprogramming.. This results in gene expression defects of numerous developmentally regulated 
genes, as well as epigenetic instability involving DNA hypermethylation, the loss of active 
chromatin marks and the accumulation of repressive marks (Cortázar et al., 2011; Cortellino et al., 
2011; Hajkova et al., 2010). TDG was also found to be essential for recruiting additional 
coregulators such as  the acetyltransferases CBP/p300, as well as other histone modifying proteins, 
to target genes (Cortázar et al., 2011; Cortellino et al., 2011). Surprisingly, the loss of TDG did 
not affect mutation frequency associated with classical base damage suggesting that its 
contribution to base repair is unlikely to account for its essential function (Cortázar et al., 2011; 
Cortellino et al., 2011).  These findings are consistent with a central role of TDG in gene-specific 
demethylation and epigenetic stability. 
Despite the importance of TDG in active DNA demethylation and gene transcription, its 
role in in post embryonic development and cellular homeostasis is unclear. Such studies could 
provide considerable insight into the role of TDG in human diseases that involve widespread 
transcriptional and epigenetic abnormalities, such as cancer. In cancer, the genome undergoes 
widespread changes in the methylation landscape that is believed to contribute to disruption in cell 
cycle control, angiogenesis and invasion. Specifically, global DNA hypomethylation of the 
genome in combination with hypermethylation of the promoter regions of many tumor suppressor 
genes represent hallmarks of all cancers (Jones and Baylin, 2002, 2007). These de novo changes 
in the methylation landscape lead to aberrant regulation of a large set of genes that promote cellular 
growth, angiogenesis and proliferation (Jones and Baylin, 2002, 2007). For example, 
hypermethylation of tumor suppressor genes, such as p15ink4b and HIC1, contributes towards their 
silencing and can also predispose genes to mutations via spontaneous deamination of 5-
methylcytosine to thymine (Shen and Laird, 2013).   
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To determine the role of TDG in adult mice, we used an inducible Cre/Loxp system to 
circumvent embryonic lethality.  Herein, we demonstrate that global Tdg deletion in adult mice 
leads to hepatocellular carcinoma (HCC) and hepatoblastoma (HB). Surprisingly, the onset of liver 
cancer did not involve the cirrhotic/ fibrotic (NCF) pathway and was highly prevalent in male 
mice. RNAseq analysis of livers from TDG deleted mice indicated a dysregulation in metabolism 
and p75NTR signaling, and upregulation in several cancer relevant pathways (MAPK, HIPPO, 
TGF) compared to livers from age matched control mice. Dysregulation in metabolism is 
characteristic of non alcoholic fatty acid liver disease (NAFLD), a pathophysiological condition 
which ultimately leads to HCC and is found predominantly in males (Hashimoto et al., 2009). In 
combination with increased MAPK and HIPPO signaling cascades which promote liver cell 
proliferation and growth, our study provides evidence that a loss or dysregulation of TDG could 
potentially predispose mice to HCC through the NCF-NAFLD pathway of liver cancer. 
3.2 Results 
3.2.1 Generation of Tdg fl/-; UB-cre/ERT2+ mouse line  
To circumvent embryonic lethality associated with embryonic TDG deletion and determine 
its role in adult mice, a UBC-Cre-ERT2 transgenic mouse line was used. UBC-Cre-ERT2 contains 
an inducible Cre-ERT2 under the control of the ubiquitin C promoter (UBC) which allows for 
widespread expression of the Cre recombinase.  The Cre-ERT2 is composed of Cre recombinase 
fused with a mutant form of estrogen receptor, which is activated exclusively in the presence of 
tamoxifen (TAM). This line was bred with a floxed conditional allele of Tdg targeting exon 2, 
resulting in efficient deletion of TDG in the whole body.  
 Using this system, a Tdg fl/-;UB-Cre/ERT2+ mouse line was generated containing a single 
integrated copy of the Cre-ERT2. To test the efficiency of recombination, Tdg fl/-;UB-Cre/ERT2+ 
mice (8 weeks of age) were treated once per day for 5 days with TAM by intraperitoneal injections 
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(Figure 3.1 A, B).  Four weeks after the final treatment, mice were euthanized, and a variety of 
tissues were analyzed for TDG knockout by western blot. Efficient recombination of TDG was 
observed in all tissues tested, including brain, liver, colon, spleen, lung, thymus and heart (Figure 
3.1 E and data not shown). Mouse embryonic fibroblasts were also generated from these mice and 
treated with 4-hydroxytamoxifen (4OH-TAM) for 72 hours prior to the assessment of TDG 
deletion (Figure 3.1 C, D). Consistent with the in vivo findings, 4OH-TAM treatment resulted in 
efficient deletion of Tdg exon 2 and a loss of TDG at the protein level.  
 
3.2.2 Hepatocellular carcinoma in Tdg fl/-; UB-cre/ERT2+ mice  
 
The treatment of 8-weeks old Tdg fl/-; UB-cre/ERT2+ (TDGKO) mice with TAM resulted in 
efficient knockout of TDG in all tissues tested (Figure 3.1 E). These mice were compared to Tdg 
fl/fl mice (control) also treated with TAM at 8 weeks of age. 
Over the course of aging, the TDGKO mice failed to display any obvious phenotype and 
remained healthy. In contrast, knockout mouse models of CBP and TETs, which interact with TDG 
and contribute towards its activity, display an immune related phenotype (Cimmino et al., 2015; 
Kang-Decker et al., 2004). For instance, the embryonic deletion of TET1 and TET2 leads to the 
development of B-cell lymphoma, whereas, CBP conditional deletion in mice causes T-cell 
lymphomagenesis (Cimmino et al., 2015; Kang-Decker et al., 2004). Based on these findings, we 
predicted that a dysregulation of TDG in the whole body would compromise the immune system 
and promote B and/or T-cell malignancies.  To determine alterations in the immune system upon 
TDG knockdown, we performed immunostaining of cells from lymph nodes, spleen and/ or 
thymus tissues from a cohort of control and TDGKO mice. The cells from these mice were co-
stained with a pan-leukocyte marker (CD45), as well as antibodies specific for B (CD19) or T-
cells (CD3, CD4, CD8). However, immunophenotyping of 4 month and endpoint mice failed to 
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detect any drastic changes in the total abundance of these cells (Figure 3.2 B-D). Although a slight 
increase in B-cells was prevalent in the spleen and lymph node of endpoint TDGKO mice, it was 
not comparable to the Tet1-/- model which displayed an approximately 4-fold increase in B-cell 
population compared to wild-type mice. Therefore, we disregarded a potential involvement of 
TDG in the immune system phenotype.  
 After approximately 20 months post-TAM injections, a significant number of TDGKO mice 
began showing a drastic decrease in total body weight. Upon euthanasia of these TDGKO mice, we 
observed an increased prevalence of hepatocellular carcinoma (HCC) compared to the control 
cohort (n= 8, Gehan-Breslow-Wilcoxon test p < 0.0001) (Figure 3.3 A, B). Hematoxylin and eosin 
staining (H&E) and immunohistochemistry of the tumor tissues with glutamine synthetase (GS), 
which is a marker of HCC in humans and mice (Salleng et al., 2015), were positive for HCC 
(Figure 3.3 C-L).  
Reticulin is a type of connective tissue fiber and is composed of type III collagen secreted 
by reticular cells. Reticulin staining assists in the assessment of hepatic plate architecture and 
thickness. The reticulin stain is also is clinically used to diagnose HCC and differentiate it from 
non-malignant lesions in the liver tissue. In general, absent or weak reticulin staining that indicates 
a thickened trabeculae (> 3 cell thick) supports the presence of HCC (Bergman et al., 1997; Nejak-
Bowen and Monga, 2011). Trabeculae is composed of dense collagenous tissue that appears in the 
form of a beam, strut or a rod anchoring different cells and/ or tissues within an organ.  The reticulin 
staining of TDGKO tumors indicated weak and /or thickened plate architecture (> 3 cell thick 
trabeculae) compared to control mice (Figure 3.3 J-L, T-V), which supports the diagnosis of HCC 
in mice. Interestingly, the pathology analysis indicated that HCC in TDGKO  
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Figure 3. 1 Efficient deletion of Tdg ex vivo and in vivo. 
 
(A) Schematic of the mouse TDG genomic structure showing the location of the loxp sites.  
(B) Schematic of the experimental mouse model and conditions used in this study. 
(C-D) Treatment of Tdg fl/fl and Tdg fl/-; UB-cre/ERT2+ MEFs with 100 nM 4-hydroxytamoxifen 
causes efficient recombination of Tdg exon 2 and loss of TDG at the protein level.   
(E) Conditional deletion of TDG in adult mice. Intraperitoneal injection of 15 mg tamoxifen over 
a 5-day period in 8-week old Tdg fl/fl and Tdg fl/-; UB-cre/ERT2+ mice causes efficient knockdown 
of TDG at the protein level. Tissues were harvested from these mice 4 weeks after the last 
tamoxifen injection, protein extracts were prepared and analyzed by immunoblotting using anti-
TDG antibody (1:3000). 
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mice originated independent of fibrosis or cirrhosis since all the tissues examined failed to show 
any signs of inflammaiton induced scarring which is indicative of liver damage.  
 
3.2.3 Hepatoblastoma occurs in Tdg knockout mice with pre-existing HCC 
 
Hepatoblastoma (HB) is a poorly differentiated and primitive hepatic tumor, which is 
known to originate from immature fetal liver cells and primarily affects children from infancy to 
3 years of age (Bhusari et al., 2015). In mice, however, HB is known to occur in a background of 
preexisting HCC, with an onset of HB being associated with increased prevelance of HCC (Bhusari 
et al., 2015; Turusov et al., 2002). In the TDGKO mouse model, a few mice presented both HCC 
and HB (Figure 3.3 M – V), which was found to be negative for the GS stain (Figure 3.3 S). This 
was to be expected since GS is an HCC specific stain (Salleng et al., 2015), which distinguishes it 
from other liver abnormalities, such as hepatic adenoma and HB.  However, the earliest case of 
hepatoma formation was observed in a 19 month old TDGKO mice (17 months post TAM), which 
displayed an overall normal liver with two tumor foci (Figure 3.3 C). These tumor foci were 
positive for the GS stain (Figure 3.3 C, H, I) and displayed significantly reduced reticulin staining 
pattern (Figure 3.3 K, L) compared to the adjacent normal liver (Figure 3.3 G, J), which is 
consistent with HCC. In addition, HB was found exclusively in the presence of advanced HCC in 
aged TDGKO mice (> 2 years old). These observations, in addition to evidence from previous 
studies (Bhusari et al., 2015; Turusov et al., 2002), led us to conclude that the HB in our mice 
originated from a pre-existing and well developed HCC.  
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Figure 3. 2 Conditional deletion of TDG does not demonstrate an immune-related 
phenotype  
 
 (A) Genetic crosses of Tdg+/- and Tdg fl/fl; UB-cre/ERT2+ mice generate Tdg fl/-; UB-cre/ERT2+ 
genotype and follow Mendelian ratios 
(B-D) Conditional deletion of TDG in adult mice followed by immunophenotyping using 
antibodies specific for the pan-leukocyte marker (CD45), B-cells (CD19), or T-cells (CD3, CD4 
and CD8) in the spleen, thymus and/or lymph node tissue. The immunophenotyping was 
performed in the spleen tissue of 4-month old and end-point mice (D), thymus tissue of mice that 
are 4-month post TAM (E), and the lymph node of endpoint mice (F).  
 
 
112 
 
 
113 
 
Figure 3. 3 Loss of TDG predisposes mice to a high prevalence of hepatocellular carcinoma 
(HCC) and hepatoblastoma (HB). 
 
(A) Tdg knockout mice develop HCC and HB between 17 – 25 months post tamoxifen injections 
compared to control Tdg fl/fl mice (Gehan-Breslow-Wilcoxon test: p < 0.0001).   
(B) HCC in mice is more prevalent in males compared to female mice. 
(C) Hematoxylin and eosin (H&E) stained sections and glutamine synthetase stained sections 
indicate that mouse livers contain multiple foci of hepatocellular carcinoma (HCC-1 and HCC-2) 
with adjacent normal liver (N).  
(D-F) High power image areas of tumors showing H&E stain of normal liver (D), HCC-1 (E) and 
HCC-2 (F).  
(G-I) High power image areas of tumors of glutamine synthetase staining showing positive zone 
three hepatocyte staining of normal liver (G) and complete block staining in hepatocellular 
carcinoma HCC-1 (H) and HCC-2 (I).  
(J-L) High power image areas of tumors showing reticulin stain of normal liver (J) and HCC-1 (K) 
and HCC-2 (L) tumor foci. 
(M) Low power hematoxylin and eosin stained section showing mouse liver displaying 
hepatoblastoma (HB) with an adjacent foci of hepatocellular carcinoma (HCC) and normal liver 
(N).  
(N-P): High power image of areas of (N) normal liver, (O) hepatocellular carcinoma and (P) 
hepatoblastoma.  
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(Q-S): High power image of glutamine synthase staining showing positive zone three hepatocyte 
staining in (Q) normal liver, complete block staining in (R) hepatocellular carcinoma and absent 
staining in hepatoblastoma (S).  
(T-V) High power image areas of tumors showing reticulin stain of normal liver (T) and HCC (U) 
and HB (V). 
Scale bars: Low power H&E staining images, 1mm; High-power field images, 100 µm. 
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3.2.4 Tdg deletion is maintained in aged Tdg fl/-; UB-cre/ERT2+ mice 
 
To determine if TDG protein is reconstituted over the course of aging, it became important 
to determine if the Tdg fl/- cells that escape lox-recombination were able to reconstitute TDG over 
time. Hence, we prepared lysates from the liver, spleen, brain and lung tissues from control and 
TDGKO groups of mice and determined TDG protein levels by western blot (Figure 3.4 A -C). The 
above mentioned tissues were analyzed since they exhibit a relatively high level of TDG protein 
in control animals (Figure 3.1 E).  The average deletion of Tdg remained relatively high in the 
tissues tested from 1 - 4 month (early) and 2 year old (end point) mice (Figure 3.1 E, 3.4 A, and 
3.4 B). Thus, the Tdg ∆/- cells do not confer an observable competitive disadvantage  in comparison 
to the Tdg fl/fl cells in TAM-treated Tdg fl/-; UB-cre/ERT2+ mice. In contrast, the levels of TDG 
seemed to rise over time in the spleen which has a relatively high rate of cellular proliferation 
(Figure 3.4 B, C). Importantly, TDG levels did not decrease appreciably in tissues with a low rate 
of proliferation such as the brain, liver, and lung, which suggests that TDG is less important for 
the continued viability of nondividing cells. Together, these results indicate that the loss of TDG 
in TDGKO mice is maintained over the aging process, however, rapidly dividing tissues seem to 
reconstitute TDG potentially from cells that escaped lox recombination and remained Tdg positive. 
 
3.2.5 Transcriptional profiling of TDGKO mice  
 
The TDGKO mice displayed an increased incidence of HCC compared to the control mice. 
The observation that a TDG deletion is maintained over the aging process in mice that eventually 
develop HCC prompted us to identify genes that are dysregulated stemming from the loss of TDG. 
Hence, we performed RNA sequencing analysis of HCC from TDGKO mice using livers of age/sex 
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matched Tdg fl/fl mice as control (Figure 3.5 A - C). The RNA-seq was validated by analyzing the 
expression of several upregulated and down-regulated genes with a greater-than-tenfold difference 
in expression between the control and TDGKO HCC datasets (Figure 3.5 D, E). The PCA analysis 
of the RNA-seq showed that the tumors display a very distinct transcriptional profile compared to 
control livers (Figure 3.5 F). Interestingly, among genes with a greater-than-twofold difference in 
expression, roughly three-times more genes were found to be downregulated in TDGKO HCC 
(Figure 3.5 G). This finding is consistent with the role of TDG as a transcriptional co-activator.  
Correlation of the TDGKO HCC transcriptome to previously published datasets (Bhusari et al., 
2013; Thomson et al., 2016) depicted a very disctinct transcriptional profile, although similarities 
were found when comparing certain upregulated and downregulated genes (Figure 5 H). These 
results suggest that HCC in the TDGKO mice possess a novel transcriptional profile than has been 
previously reported.  However the majority of these differences could be attributed to aberrant 
transcription that is inherent to tumor cells. To establish a causative correlation between TDG 
deletion and HCC formation, it became important to identify gene signatures of livers deficient in 
TDG. Hence, we extracted livers from TDGKO and control mice four months post TAM injections, 
and performed RNA sequencing of the tissues (Figure 3.6 A – B). We identified approximately 
1600 differentially expressed genes (q-score < 0.05) (Figure 3.6 C). Hierarchial clustering of the 
differentially expressed genes from young (four-months post TAM injections) and endpoint 
cohorts of mice showed distinct transcriptional profiles. The RNAseq was found to be highly 
reproducible,  with replicates from each cohort clustering together and forming distinct groups 
depending on the TDG status and age of the mice (Figure 3.6 C). Surprisingly, the differentially 
expressed genes resulting from TDG deletion in livers from 4 month old mice appeared to be 
further dysregulated upon HCC formation (Figure 3.6 D) . This suggested a potential overlap  
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Figure 3. 4 The conditional deletion of TDG is maintained during aging. 
   
(A) Brain, liver, lung and spleen tissues from control and TDGKO mice were analysed by western 
blot with TDG (1:5000) and VINCULIN (1:20000) antibodies. The tissues were harvested at 4 
month and 24 months post TAM injections.  
(B) Western blot analysis of the brain, liver, lung and spleen tissues from control and TDGKO mice 
with HCC (TDG 1:5000 and VINCULIN 1:20000). The control and TDGKO mice are age-matched.  
(C) Quantification of western blots (from B) for brain, liver, lung and spleen tissues  
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Figure 3. 5 Transcriptome analysis of HCC from TDG knockout mice 
 
(A-B) TDG deletion is maintained in the HCC tumors isolated from TDG knockout mice at the 
(A) mRNA and (B) protein level. 
(C) RNAseq of HCC from TDG knockout mice and normal age/sex matched control mice.  
(D, E) RNA-seq validation using primers against specific upregulated (D) and down-regulated 
(E) genes showing a greater than 10-fold change between the control and TDGKO HCC datasets.  
(F) PCA plot comparing the expression of control and TDGKO HCC datasets.  
(G) A piechart depicting percentage of genes with two-fold difference in expression (Control 
FPKM/ HCC FPKM).  
(H) Comparison of TDG knockout HCC RNAseq with previously published transcriptome 
analysis of HCC in mice. Yellow circle represents microarray of HCC performed by Bhusari et 
al. (2015); whereas, the green circle represents genes from the RNAseq performed by Thomson 
et al. (2016).  
 
 
121 
 
 
122 
 
between gene signatures of TDGKO livers and HCC.  Through further statistical analysis, we found 
that the transcription profile of a significant number of genes were dysregulated in both TDGKO 
livers and HCC (Figure 3.6 E, F).  Hierarchial clustering of these genes allowed us to establish a 
transcriptional profile that could be differentiated based on TDG status, with the TDGKO livers 
clustering much closer with TDGKO HCC than the control groups (Figure 3.7 A).  These results 
demonstrate that a deletion of TDG causes transcriptional dysregulation in livers that could 
potentially predispose them towards HCC.   
Pathway analysis of the upregulated and downregulated genes (1.5 fold compared to 
control mice livers) was performed using the KEGG and REACTOME databases. Pathway 
analysis of downregulated genes showed dysregulation of liver metabolism, retinoid metabolism 
and bile acid regulation, as well as, a downregulated p75 NTR receptor signaling (Figure 3.7 B). 
Dysregulation of metabolism is a major risk factor of HCC originating via the non-alcoholic fatty 
acid liver disease (NAFLD) pathway which occurs predominantly in male patients (Hashimoto et 
al., 2009). This finding agrees with our data since a cohort of metabolically relevant genes were 
downregulated in TDGKO male mice (Figure 3.7 D), which also displayed an increased onset of 
HCC and increased weight compared to age-matched female mice (Figure 3.3 B, 3.7 E, 3.7 F). 
Pathway analysis of the upregulated genes upon TDG deletion depicted an increase in several 
cancer relevant pathways, such as MAPK and HIPPO signaling (Figure 3.7 C), which are known 
to contribute towards increased hepatocyte proliferation and growth (Lu et al., 2010; Zhou et al., 
2009a). These results suggest that the loss of TDG could predispose mice to HCC through non-
cirrhotic/ fibrotic (NCF)-NAFLD, and could serve as a diagnostic marker of liver cancers 
originating via this pathway. 
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3.2.6 TDG as a potential prognostic marker of liver cancer in patients 
 
Analysis of the mutational status of TDG in several cancers suggests that a significant 
subset of patients with liver cancer have mutations in the TDG gene (Figure 3.8 A). These 
mutations could potentially dowregulate the Tdg transcript and affect TDG function. In order to 
determine if a lower level of TDG is associated with liver cancer in patients, we analyzed the 
TCGA HCC dataset and stratified patients based on their history of liver diseases. In accordance 
with our data, TCGA analysis revealed that males without a history of liver disease (no cirrhosis 
or fibrosis associated liver damage) have significantly lower levels of the TDG transcript and 
higher mortality relative to male/ or female patients with a history of alcoholism or hepatitis 
infection (Figure 3.8 B - E). Although it remains unclear if a lower TDG level predisposed these 
patients to cancer, this finding agrees with our data that TDGKO HCC shows a male gender bias 
and develops from a non-cirrhotic and non-fibrotic pathway. 
 
3.3 Discussion  
 
TDG is a BER protein which has been shown to play an instrumental role in gene 
regulation. Studies using mouse models demonstrate that TDG deletion leads to gene specific 
DNA hypermethylation and aberrant transcription of developmentally relevant genes, resulting in 
embryonic lethality. However, despite its importance the role of TDG in post embryonic 
development remains unknown. In this study, we demonstrate for the first time that the conditional 
deletion of Tdg in adult mice predisposes them to a high prevalence of HCC through the non-
cirrhotic/fibrotic (NCF) pathway of liver cancer. High throughput sequencing of tumors  
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Figure 3. 6 Transcriptional profile of hepatocytes deficient in TDG compared to TDGKO 
HCC 
 
(A) Western blot analysis of the TDG in Tdg fl/fl livers compared to age/sex matched Tdg fl/-; UB-
cre/ERT2 + (TDGKO) mice livers. Both mice were injected with TAM, as indicated in the 
methods section, and allowed to age for 4 months prior to tissue harvest.  
(B) The characteristics and identity of mice used for RNA-sequencing analysis. The age of the 
mice is indicated post tamoxifen injection. All of the mice were injected at 8 weeks.  
(C) Heatmap depicting hierarchial clustering of 1624 differentially expressed genes (identified 
from the RNAseq of 4 month old control and TDGKO livers) with endpoint control and TDGKO 
HCC transcriptomes. These genes were identified from a cutoff of a q-score < 0.05. 
(D) Comparison of the 1624 differentially expressed across all samples. The log10 of fold 
changes was used to visualize the downregulated and upregulated genes.  
(E, F) Comparison of upregulated and downregulated genes between TDGKO livers and HCC. 
The fold-changes of 1625 differentially expressed were generated by dividing the FPKM values 
of control samples with age/sex matched FPKM values of TDGKO samples. Genes with a 1.5 and 
2-fold difference in expression were then analyzed for overlap between the TDGKO livers and 
HCC datasets. 
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Figure 3. 7 Gene signature of TDGKO hepatocytes and HCC 
 
(A) Heatmap and hierarchical clustering of overlapping upregulated and downregulated genes 
between the TDGKO livers and HCC RNAseq datasets. All of the genes depicted display a 1.5-
fold difference compared to their respective control cohorts.  
(B-C) KEGG and REACTOME pathways analysis of the downregulated (B) and upregulated (C) 
genes.  
(D) Heat map and hierarchical clustering of several genes relevant to the p75NTR receptor 
signaling, metabolism and bile-acid biosynthesis.  
(E-F) The conditional deletion of TDG in whole body causes a dysregulation in total body weight 
exclusively in the male population (E), relative to the control mice. 
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and livers from male mice deficient in TDG demonstrated a defect in metabolism, which is 
concomitant with non-alcoholic fatty liver disease (NAFLD) phenotype.  Further support for 
NAFLD is provided by the finding that the HCC occurred predominantly in male mice, which also 
displayed increased weight gain and obesity with age. These findings agree with studies showing 
that NAFLD-induced HCC occurs predominantly in males, and is associated with obesity 
(Hashimoto et al., 2009; Kettner et al., 2016). In concert with a protective role of TDG against 
carcinogenesis in the liver, we find that several of the cancer relevant pathways, such as MAPK 
and HIPPO signaling, were upregulated upon TDG deletion in the liver. These findings 
demonstrate that TDG plays a tumor suppressive role in the liver tissue, and its deletion leads to a 
defect in metabolism relevant genes which potentially predispose these mice to NCF-NAFLD 
pathway of HCC.  
HCC is the predominant form of liver cancer, and the second leading cause of cancer 
related mortalities worldwide (Mittal and El-Serag, 2013), with over 500 million cases per year. 
The majority of HCC occurs in a background of hepatic inflammation which is known to contribute 
towards tissue damage, scarring (fibrosis) and cirrhosis (Yang et al., 2011). Hepatitis viral 
infection and alcoholism are also known to increase the risk of HCC by inducing fibrosis and 
cirrhosis. Although HBV infection can cause HCC independent of cirrhosis, the vast majority (70 
– 90%) of HBV-induced HCC occurs in cirrhotic livers (Lemon and McGivern, 2012; Mittal and 
El-Serag, 2013; Yang et al., 2011). Continued scarring of the liver tissue during cirrhosis leads to 
persistent cell regeneration, which contributes towards the malignant transformation of 
hepatocytes (Dapito et al., 2012; Haybaeck et al., 2009; Mittal and El-Serag, 2013; Moeini et al., 
2012; Yang et al., 2011).  
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 In our model, we find that TDG deletion leads to HCC independent of cirrhosis or fibrosis, 
which indicates a lack of inflammation induced liver damage. In order to delineate deregulated 
pathways upon TDG deletion, high throughput RNA sequencing of the solid tumors and normal 
livers was performed followed by gene enrichment analysis. It was found that a loss of TDG leads 
to a downregulation of p75NTR signaling. The upregulation of p75NTR signaling pathway has been 
directly associated with increased fibrosis and cirrhosis in patients (Amoras et al., 2015), hence, a 
downregulation of this pathway agrees with a lack of cirrhosis/fibrosis in TDGKO livers. In 
addition, both the MAPK and HIPPO signaling pathways were found to be upregulated which have 
been previously implicated in liver cancer by contributing towards increase hepatocyte 
proliferation and loss of cell cycle control (Delire and Stärkel, 2015; Zhou et al., 2009b). In Hippo 
signaling, the MST1 and MST2 kinases, along with LATS1/2 and MOB1 regulate the activation 
of YAP/TAZ oncogenes (Zhou et al., 2009a). Several studies have demonstrated that YAP/TAZ 
activation directly promotes liver outgrowth and spontaneous HCC in mice (Lu et al., 2010; Zhou 
et al., 2009a). These oncogenes are also known to trans-activate the MAPK signaling to promote 
HCC in mice (Moeini et al., 2012; Zhang et al., 2015; Zhou et al., 2009a), indicating a potential 
for crosstalk between the two pathways.  These findings suggest that TDG potentially function as 
a tumor suppressor in liver via suppression of the HIPPO and MAPK signaling pathways. 
Downregulation of several metabolism relevant genes was also found upon TDG deletion 
in the liver tissue, which is known to cause metabolic syndrome in humans and mice (Phillips et 
al., 2006).  Metabolic syndrome is generally associated with central obesity, with an accumulation 
of the adipose tissue particularly around the waist and trunk.  Metabolic syndrome leads to a defect 
in glucose metabolism and insulin resistance, and is the number one cause of liver cancers that 
originate via the NAFLD pathway (Kettner et al., 2016). NAFLD is found in approximately 30 –  
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Figure 3. 8  Relationship between TDG levels and clinically aggressive form of HCC. 
 
(A) Mutation analysis of the TDG gene in tumors reveals that it is commonly mutated in liver 
cancer, as well as other tumors  
(B-C) Male HCC patients with no history of liver disease die significantly faster compared to 
male patients with alcoholism/hepatitis induced HCC (B) and females with no history of liver 
disease (C).   
(D-E) Male patients with no history of liver disease possess statistically significant lower Tdg 
mRNA levels compared to patients with cirrhosis dependant HCC with a history of alcoholism or 
hepatitis B/C infection (Males in D, Females in E).  
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40 % of the general population and up to 95 % of those with morbid obesity (LaBrecque et al., 
2014). Excessive fat accumulation induces liver injury, inflammation and regeneration, which 
leads to cirrhosis and fibrosis in a process called non-alcoholic steotohepatitis (NASH)  (Kettner 
et al., 2016). Although NAFLD can progress to HCC through NASH, there are a subset of patients 
with NAFLD that develop HCC independent of NASH, however, the mechanism remains unclear 
(Guzman et al., 2008). Our study provides evidence that a loss of TDG potentially leads to a 
metabolic syndrome and NAFLD in mice through downregulation of genes important in 
metabolism. This in turn facilitates an onset of HCC through the novel NCF-NAFLD pathway that 
is independent of cirrhosis/NASH.   
The lack of proper mouse models that develop NAFLD from metabolic syndrome has 
significantly delayed our understanding of metabolism induced hepatocarcinogenesis. In this 
study, we demonstrate for the first time that TDG deletion leads to liver cancer in mice that involve 
a dysregulated NCF pathway that includes several metabolism related genes characteristic of 
NAFLD associated HCC. Consistent with these findings, TCGA analysis revealed a reduction of 
Tdg transcript in male patients that develop HCC from the NCF pathway, although evidence of 
NAFLD was inconclusive in these patients. These patients were found to have a clinically worse 
outcome compared to females without a history of liver disease, or patients with cirrhosis induced 
HCC (Alcoholism or HBV/HCV infection). DNA methylation patterns are known to be 
deregulated in a host of tumor types, including HCC (Lian et al., 2012; Sproul and Meehan, 2013; 
Thomson et al., 2016).  In addition to changes in DNA methylation, recent studies show that levels 
of 5hmC are reduced in rapidly proliferating hepatocytes that have undergone hepatectomy (Neri 
et al., 2015; Nestor et al., 2015; Thomson et al., 2016). This is significant since a reduction in 
5hmC levels has previously been linked to an elevated rate of proliferation in tumor cells (Lian et 
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al., 2012). These findings suggest that deregulation of active DNA demethylation pathway could 
be a potential precursor to HCC formation. Future studies are necessary to determine if TETs and 
TDG play a role in maintaining epigenetic stability in hepatocytes, and if deregulation of the 
methylome is sufficient in predisposing mice to HCC in vivo.  
 
3.4 Methods 
 
3.4.1 Generation of the TDGKO mice  
 
All mouse experiments were done in compliance with the Institutional Animal Care and 
Use Committee guidelines at London Regional Cancer Center at Western University. For the 
conditional deletion of Tdg, Tdg fl/fl mice were bred with UBC-cre/ERT2 mice to generate Tdg fl/fl; 
UBC-cre/ERT2+ mice. These mice were then bred with the Tdg+/- mice to generate the Tdg fl/-; 
UBC-Cre/ERT2+ experimental genotype. The Tdg+/- mice were generated by mating the Tdg +/fl 
mice with a deletion cre mice. In this model, exon 2 of Tdg is targeted for deletion, which has 
previously been shown to generate an efficient knockdown of the TDG protein.  The UBC-
cre/ERT2 mouse line utilizes the ubiquitin C promoter to express a tamoxifen inducible form of 
cre (cre-ERT2) in the whole body, which translocate to the nucleus upon activation and catalyzes 
the recombination of loxp sites to facilitate protein deletion (Ruzankina et al., 2007). In this 
experiment, adult (8 weeks old) Tdgfl/-;UB-Cre/ERT2+ and age/sex matched Tdg fl/fl controls were 
intraperitoneally injected with 3 mg TAM daily for 5 days to facilitate efficient TDG deletion, and 
then monitored during the course of aging. 
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3.4.2 Immunohistochemistry (IHC) and Reticulin Staining  
 
Immunohistochemistry was performed on unstained formalin fixed, paraffin embedded 
sections of tissues. Briefly, 4 µm sections of the tissues were collected on charged glass slides and 
then were de-paraffinzed in xylene and rehydrated through a decreasing graded ethanol series. This 
was followed by heat-induced antigen retrieval. Then the tissue section was incubated with 3% 
peroxide blocking solution to block endogenous peroxidase activity. Immuno-blotting was then 
performed using glutamine synthetase and anti-rabbit secondary antibody (1:1000). The tissue 
sections were then incubated with peroxidase substrate (ImmPACT DAB Vector Laboratories SK-
4105) and 3,3-diaminobenzidine (DAB) was used to visualize all immune reactions. The tissue 
sections were counterstained with hematoxylin.  
The reticulum stain was performed using the reticulum stain kit as per manufacturer 
guidelines (Abcam, AB150684). Briefly the tissue sections were deparaffinized and then 
rehydrated in increasing ethanol series. The tissue slides were incubated in potassium 
permanganate solution, followed by potassium metabisulfite solution until the section went 
transparent. The tissue was then incubated with ferric ammonium sulfate, ammoniacal silver, 
formalin, gold chloride and sodium thiosulfate solution with intermittent rinsing with distilled 
water. The slides were counterstained using nuclear fast red solution and then dehydrated with 
absolute ethanol. The sections were then mounted in synthetic resin for imaging.  
 
3.4.3 qPCR 
 
Total RNA from tissues was extracted using an RNAzol solution as per manufacturers 
protocol (ThermoFisher). Prior to RNA extraction, the tissues were flash frozen in RNAzol and 
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kept at -80 oC. The cDNA was synthesized using the Applied Biosystems Reverse Transcription 
Kit as per manufacturer guideline. Quantitative PCR wase performed using a SYBR Green-
detection system (Applied Biosystems) using primers outlined in Table 3.2. Transcript abundance 
was normalized to Gapdh mRNA.  
 
3.4.4 RNA sequencing and Bioinformatic analysis 
 
For the RNA-seq, the sample quality was assessed using the Agilent 2100 Bioanalyzer. 
Qualifying samples were then prepped following the standard protocol for the NEBnext Ultra ii 
Stranded mRNA (New England Biolabs). Sequencing was performed on the Illumina NextSeq 500 
with Paired End 42bp × 42bp reads. The raw data was aligned to the mm10 mouse genome using 
the STAR aligner and gene list was generated using cufflinks. Differentially expressed gene list 
was generated using q < 0.05 as the cutoff for significance. The heatmap was generated using the 
Bioconductor gg-plot addon for the R software and Morpheus from broad institute. For the TCGA 
analysis, the data was downloaded using the firehose website, and analyzed using the R-software. 
GraphPad PRISM 5.0 was used for generating the Kaplan-Meier curves.  
 
3.4.5 Immunophenotyping 
 
The mice were euthanized and within 15 minutes, the spleen tissue was harvested and 
placed in 3 ml ice-cold 1 X PBS buffer. Samples were then homogenized and transferred to 14 ml 
BD falcon tubes. Then, 2 ml of the ACK lysis buffer (150 mM NH4Cl, 0.01 mM NaHCO3, 0.2 
mM EDTA) was added and cells were incubated on ice for 5 min to facilitate red blood cell lysis. 
Samples were then spun down at 2100 rpm and re-suspended in 1 ml FACS buffer (10 % FBS, 2 
mM EDTA in 1x PBS buffer) and cells counted. After counting the number of cells, the samples 
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were spun and re-suspended at 10,000 cells / µl and 50 µl was added per well (1 million cells) in 
a 96 well plate. The cells were treated with 1 µg of FC block (CD16/32) for 15 min, then incubated 
with the antibody cocktail (CD45-PE Cy7, CD3-FITC, CD19-APC, CD14-PE—1 µg each in 
FACS buffer) for 1 hr on ice in dark and then washed twice with FACS buffer. Samples were then 
analyzed on BD-FACS 4 color flow-cytometer in triplicates. Unstained samples (i.e. samples 
treated with FC block but not the antibody cocktail) are used as negative control 
 
3.4.6 Statistical analysis 
 
The data represented in qPCR (for mRNA expression) and Image J western blot 
quantification figures, using the vinculin for normalization, are representative of at least three 
independent biological replicates. For the 3C experiment, the data from gel electrophoresis was 
assessed by the ImageJ software, using the untreated lane for normalization. All western blots are 
representative of at least duplicate experiments. Statistical analyses were performed using 
GraphPad Prism 5.0, employing the Student’s t-test (2 groups), or ANOVA with Tukey post-hoc 
(3 groups or more). All p-values over 0.05 were deemed not significant.  Significance is indicated 
as follows: *, p < 0.05; NS: not significant. 
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Table 3. 1 List of qPCR primers used in this chapter 
 
Primer 
Name 
Forward (5’ – 3’) Reverse (5’ – 3’) 
Gapdh AAGGTCATCCCAGAGCTGAA CTGCTTCACCACCTTCTTGA 
Lef1 TCTGCCCTGTGAAGTGTCTG AATGAACTGCAAACGGGTTC 
Tet1 ACCACCCAGATCATCCCATA CCTGTCTCAGTCCCTCAAGC 
Tenm4 CAGCCTGTGACTTCCTCCTC CTTGCCTGTTTCCTCTCTGG 
Dkk3 TGAGGCAGTGGCTACACAAG GCTGGTATGGGGTTGAGAGA 
Rac3 ACTGCTGGCCAGGAAGACTA CAGAAGGATGGGTGTGTGTG 
Hey 2 ACCAGAGGCTCATTGACACC CCTCTCCCCAAAACAGACAA 
Bmp7 CAGACCAACCTCTCCTGAGC AGGCTTGCGATTACTCCTCA 
Mst1 CTGATTTGCCTGCCTCCTGAAC AGGACTGTGTTATTGCTTGTACC
G 
Cyp2c2
9 
TCAGCCAATCCTTCACCAACTTC ACCCGTGCAATATGACAGTAGGC 
Cyp1a2 TGGCAGGTCAACCATGATGAGAA
G 
CTTTCCCAAGCCGAAGAGCATC 
Aaas TGGAGACTTCAACGGCTTCTCG GCCTTTGGCTTCAATTTCACCATC 
Cyp2c7
0 
TCCTTCACCTCGTAAGACAACGC TGCCATTACACTTGTGCCCTTGG 
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Table 3. 2 List of antibodies used for immunophenotyping experiments 
 
Antibody Company Catalogue number 
CD3 – FITC BD Pharmingen 561798 
CD45-PE-Cy7 BD Pharmingen 552848 
CD8a-PE-Cy7 BD Pharmingen 552877 
CD4-PE BD Pharmingen 553048 
CD16/CD32 (Fc 
Block) 
BD Pharmingen 553141 
CD19-PE BD Pharmingen 561736 
 
Table 3. 3  List of antibodies used in this chapter 
 
Antibody Species Company Catalogue No. 
TDG mouse Rabbit Homemade N/A 
Vinculin Mouse Sigma V9264 
Glutamine 
Synthetase (GS) 
Mouse  Santa Cruz Sc-74430 
Mouse on Mouse 
ImmPRESS 
HRP 
Mouse Vector Labs MP-2400 
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The epigenetic control of gene transcription involves changes in DNA methylation and/ or 
histone tails modification and is important for a variety of biological process. Although histone 
modifications were known to be dynamic, the 5mC mark was always considered a relatively stable 
DNA mark. Recent studies has shed light on the plasticity of DNA methylation during 
development, differentiation, somatic cell reprogramming and tumorigenesis (Cortázar et al., 
2011; Cortellino et al., 2011; Gu et al., 2011; Hassan et al., 2017; Hu et al., 2014; Métivier et al., 
2008). The active DNA demethylation system facilitates the modification or removal of the 5mC 
mark and was found to be critical for these biological processes. For instance, studies show that 
cellular reprograming and signaling in response to stimuli, such as retinoic acid and estrogen, is 
dysregulated upon TDG and/ or TET1/2/3 deletion (Hassan et al., 2017; Hu et al., 2014). TET3 
was found to be critical for methylation erasure of paternal genomes in the primordial germ cells, 
and TET3 KO mice display developmental abnormalities (Gu et al., 2011; Tsukada et al., 2015). 
Beyond embryonic development, studies have shown that a loss of TETs affect MET (Hu et al., 
2014), as well as, the reprogramming of MEFs and that TET1/2 act as tumor suppressors of the 
hematopoietic system in mice (Cimmino et al., 2015; Lian et al., 2012; Rasmussen et al., 2015; 
Weissmann et al., 2012). Studies on AML have shown that disease progression involves a drastic 
loss of 5hmC (Lian et al., 2012), which correlates with a decline in TET2 transcription (Weissmann 
et al., 2012). These studies promote TET proteins as important epigenetic regulators in cells and 
potential biomarkers and predictors of hematopoietic cancers.   
Research examining active DNA demethylation has increased tremendously since its 
discovery, yet much of the focus has been on TET proteins and very few studies report on the 
physiological relevance of TDG. This is surprising since TDG was found to be essential for 
embryonic development and maintenance of epigenetic stability in cells, which underscores its 
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importance in active DNA demethylation and development (Cortázar et al., 2011; Cortellino et al., 
2011). In addition to its glycosylase activity, TDG has an elaborate interaction networks which 
involves nuclear receptors, co-activators, and proteins within the DNA demethylation, BER, and 
NER machinery. Studies have shown that TDG functions as a scaffolding protein at certain genes 
by facilitating complex stability of co-activators such as CBP, MLL1 and TET2 (Cortázar et al., 
2011; Hassan et al., 2017). Thus, TDG participates in events that extend beyond active DNA 
demethylation, which begs into question whether its dual catalytic and scaffolding activities are 
important in gene transcription. In this study, I identified the Hic1 gene as a direct RAR-dependent 
target for TDG and show that the dual catalytic and scaffolding activities of TDG are required for 
RA-dependent gene expression of HIC1 (Chapter 2).  In addition, using a conditional knockout 
mouse model of TDG, I study the role of TDG beyond embryonic development and demonstrate 
that its deletion predisposes mice to a high prevalence of HCC (Chapter 3).   
 
4.1 The catalytic and scaffolding activities of TDG are important for gene transcription 
Retinoic acid (RA) plays critical regulatory role in a variety of biological process, such as 
establishment of the body plan during embryonic development and cell cycle control (Tang and 
Gudas, 2011;Li et al., 2004; Suzui et al., 2004).  The bioactivity of RA is mediated primarily by 
heterodimers of RAR/RXR heterodimers, which regulate the transcription of its target genes by 
recruiting coregulatory proteins, such as CBP and TDG.  Previous studies show that TDG is 
important in retinoid signaling events by facilitating the recruitment of certain co-activators and 
maintaining protein complex stability at target genes. Retinoid signaling was found to be 
compromised upon TDG deletion in MEFs, with several of the genes in the retinoid pathway being 
silenced upon TDG deletion (Cortazar et al., 2011).  These studies suggest that TDG potentially 
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functions as a scaffold and glycosylase in RA signaling cascades. In my study, I identified 
hypermethylated in cancer 1 (Hic1) as novel RA inducible target and show that active DNA 
demethylation occurs during Hic1 transcription. I found the excision of active demethylation 
metabolites 5fC/5caC at the Hic1 promoter and the recruitment of certain RAR co-activators are 
TDG dependent (Hassan et al., 2017). Overall, this study provides evidence that the dual catalytic 
and scaffolding activities of TDG are essential in retinoid signaling events.  
HIC1 is a candidate tumor suppressor (Britschgi et al., 2008), and its expression is often 
lost in solid human cancers as a result of DNA hypermethylation of its P0 promoter (Aggerholm 
et al., 2006; Chen et al., 2003; Cheng et al., 2014; Jenal et al., 2010).  In my study, I found that 
treatment of MEFs with RA led to the recruitment of an RAR complex consisting of TDG, the 
lysine acetyl transferase CBP, RXR, and TET1/2 to a conserved RARE upstream of the Hic1 P0 
promoter (Figure 4.1). The RAR complex displaced DNMT3a and led to a loss of 5mC with a 
concomitant upregulation of 5fC/5caC at the P0 promoter. Through time-course methylase assisted 
bisulfite sequencing (MAB-seq), I showed that although the 5fC/5caC metabolites continue to 
accumulate in the absence of TDG, their subsequent removal is blocked. Using kinetic ChIP 
experiments, I found that the generation of these metabolites correlated with TET2 localization, 
which shows that TET2 participates in 5mC oxidation at the Hic1 promoter. These findings 
demonstrate that the glycosylase activity of TDG is required for Hic1 transcription in response to 
RA.  In addition, RAR complex stability was hindered in the absence of TDG, since the recruitemnt 
of CBP and TET2 was abrupted in TDG knockout MEFs. Overall, these findings demonstrate that 
the dual catalytic and scaffolding properties of TDG are important for gene regulation in response 
to RA, and that TDG plays a critical role in active DNA demethylation via regulating 5fC/5caC 
turnover in MEFs (Hassan et al., 2017).  
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Future studies utilizing targeted mutations are necessary to determine if both the catalytic 
and scaffolding activities of TDG are important for gene transcription. Cortellino et al. (2012) 
showed that the catalytic activity of TDG is dispensible for embryonic development, however, 
very little is known about its scaffolding function. It would be interesting to determine if perturbing 
the interaction network of TDG can cause embryonic lethality, or lead to specific disease states.   
 
4.2 Is TDG a tumor suppressor or an oncogene? 
 
TDG was initially identified as a base excision repair (BER) protein, involved in the removal 
of mutagenic G:T and G:U mispairs from DNA. However, TDG knockout studies demonstrated 
that its deletion does not contribute to increased mutational load in cells, which is inconsistent with 
its classical base repair function (Cortázar et al., 2011). In concert with these findings, irradiation 
of Tdg null MEFs did not lead to genomic instability or a loss of proliferation compared to wild-
type MEFs (Cortázar et al., 2011). This was surprising since MBD4 deletion, which is a functional 
homologue of TDG, leads to random CpG mutations from a dysfunctional BER pathway and an 
onset of colorectal cancer in mice (Wong et al., 2002).  Through these observations it became 
apparent that although TDG participates in base repair, its loss doesn’t contribute to a 
dysfunctional BER pathway potentially through redundancy within the system.   
In addition to its role in BER, TDG appears to be involved in pathways that are relevant in 
both tumor progression and suppression. For instance, TDG was found to potentiate p53 dependent 
activation of p21 (da Costa et al., 2012) and promote the transcription of RARβ, p15ink4b, p16ink4a,  
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Figure 4. 1  The regulation of HIC1 transcription in response to RA is TDG dependant. 
 
The treatment of MEFs with RA leads to the recruitment of an RAR complex consisting of TDG, 
TET1/2, CBP and RXR. This binding correlates with chromatin looping which connects the distal 
RARE with RARE at the Hic1 locus, and active demethylation of its P0 promoter. The recruitment 
of CBP and TET2 appears to be TDG dependent. In addition, the TET2 localization was found to 
be transient and concomitant with generation of the 5fC / 5caC metabolites a the P0 promoter.  
This model provides evidence of the dual catalytic and scaffolding activities of TDG in gene 
transcription, and demonstrates a novel dynamics of active DNA demethylation in response to 
cellular stimuli.  
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and Hic1 tumor suppressor genes (Cortázar et al., 2011; Hassan et al., 2017; Thillainadesan et al., 
2012; and unpublished data). These findings would be consistent with a tumor suppressor function 
of TDG. In contrast, evidence indicates that TDG potentiates Wnt signaling cascades through its 
interaction with TCF4 (Xu et al., 2014), which is concomitant with increased TDG expression in 
high grade colorectal cancers. In addition, TDG has been shown to play a role in estrogen signaling 
cascades (Métivier et al., 2008), which are important for breast cancer proliferation and invasion.  
evaluate its role in development, it became necessary to generate a mouse model of Tdg deletion.   
In order to analyze the role of TDG in vivo, we generated a conditional knockout mouse 
model (Tdg fl/-; UB-cre/ERT2+) to circumvent embryonic lethality. We injected these mice with 
tamoxifen once they reached maturity (8 weeks) and then monitored their development over a 
period of 2 ½ years. After roughly 20 months post tamoxifen injections, the mice began to exhibit 
an increased prevelance of hepatocellular carcinoma (HCC) and hepatoblastoma (HB). 
Surprisingly, males had nearly four times higher incidence of HCC relative to female mice.   
Pathology of tumors stained positive for complete glutamine synthetase staining, and either absent 
or greater than 3 cell-thick trabeculea (reticulin stain), which is consitent with an invasive and 
metatastatic liver cancer. HCC was also found to occur independant of cirrhosis or fibrosis induced 
liver scarring.  RNA sequencing followed by pathway analysis revealed dysregulation in 
metabolism and upregulation of MAPK and HIPPO signaling pathways, which have been directly 
implicated in liver cancer. The defect in metabolism relevant genes provides evidence of NAFLD 
in TDGKO mice, which is known to occur predominantly in males. However, future studies are 
necessary to validate the onset of NAFLD in TDGKO mice through histological (Oil red O-stain) 
and serum analysis (carnitines, lipids, prostaglandins, CoAs and TCA metabolites) to establish a 
defect in liver metabolism. These studies could generate novel mechanistic insights into NAFLD 
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associated HCC that occurs indepandant of cirrhosis induced NASH, and provide potential 
biomarkers and/or druggable targets in liver cancer.  
 
4.3 TDG as a tumor suppressor in vivo  
 
In the first part of my studies, I showed that TDG is important for recruiting the co-
activators CBP and TET2, as well as, regulating the levels of 5fC / 5caC at the Hic1 locus in 
reponse to RA. HIC1 functions as a tumor suppresor in vivo, and is known to be frequencly 
silenced in cancers as a result of promoter DNA hypermethylation (Chen et al., 2003) Surprisingly, 
the Hic1 promoter was found to be hypermethylated in TDG knockout HCC relative to age-
matched normal liver (Figure 4.2). This finding is in agreement with my study on the role of TDG 
in retinoid signaling events in MEFS showing that a deleiton of TDG in vivo leads to Hic1 silencing 
via promtoer DNA  hypermethylation (Chapter 2, Figure 2.14). This indicates that TDG deletion 
promotes the targeted silencing of tumor suppressor genes by DNA hypermethylation in vivo, 
which could be a contributing factor to HCC arising from a deficiency in TDG. In addition, these 
findings demonstrate that a loss of TDG in adult mice potentially deregulates retinoid signaling 
events, which is a known feature of liver cancers (Shirakami et al., 2015).   
The onset of liver cancer in TDG deleted mice is in stark contrast with deletion of other 
members of the active demethylation machinery that are associated with an immune-related 
phenotype. The reason for these differences are currently unclear. It is conceivable that unlike the 
immune system where a loss of TDG could be compensated by redundant pathways or proteins, 
such as MBD4, it plays a very particular role in hepatocytes. Through RNAseq on livers, I found 
that a series of genes encoding liver metabolism enzymes were downregulated upon TDG deletion 
(Chapter 3, Figure 3.7D). In addition, genes important for retinol metabolism, such as Rbp1, Bco2 
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and Lrat, were all downregulated in TDG null livers (Chapter 3, Figure 3.7 D) consistent with 
previous observations. It has been established that retinoids regulate the expression of a multitude 
of genes associated with fat metabolism, and many studies support the relationship between 
defective retinoid signaling and liver disease (Shirakami et al., 2015). For instance, studies suggest 
that BCO, which is an enzyme responsible for cleaving provitamin A carotenoids to retinoids, has 
a role in modulating hepatic fat metabolism (Hessel et al., 2007).  BCO mutant mice were found 
to possess a fatty liver and are more susceptible than control mice to high fat diet-induced 
impairments in fatty acid metabolism (Hessel et al., 2007). Consistent with this finding, an analysis 
of hepatic transcriptional profile of NAFLD patients indicated that retinoids have important roles 
in mediating normal lipid metabolism in the liver and that altered retinoid signaling is associated 
with a progression of NAFLD (Ashla et al., 2010).  In addition, a study on insulin resistance 
demonstrated that an oral administration of ATRA significantly improved insulin sensitivity in a 
diet-induced mouse model of NAFLD (Tsuchiya et al., 2012), which indicates that retinoids may 
stimulate insulin sensitivity to counteract the onset of NAFLD in mice. Since TDG plays an 
essential role in retinoid signaling, it is conceivable that a loss of TDG predisposes mice to NAFLD 
due to dysregulated retinoid metabolism.  Additional studies, involving ChIP and genome-wide 
bisulfite sequencing, are needed to address the role of TDG in the control of metabolism relevant 
genes, and if TDG levels correlate with lost sensitivity to retinoid signaling events, metabolic 
syndrome and NAFLD associated HCC in mice. 
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Figure 4. 2 Transcriptional silencing of HIC1 in TDG knockout HCC 
 
 (A)  Bisulfite sequencing of Hic1 P0 promoter of HCC shows greater than 90 % methylation 
compared to age, and sex matched normal control liver 
(B) HIC1 is silenced in tumors with a hypermethylated P0 promoter relative to normal livers of 
age and sex matched control mice 
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APPENDIX 1: Hepatocellular Carcinoma in Tdg fl/-; UB-cre/ERT2+ mice 
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Figure 5. 1 Identity of the Tdg fl/-; UB-cre/ERT2+ (TDGKO) mice with hepatocellular 
carcinoma and/or hepatoblastoma 
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